00000142722024Q3--12-31FALSEFALSExbrli:sharesiso4217:USDiso4217:USDxbrli:sharesbmy:rightxbrli:purebmy:lawsuitbmy:paymentiso4217:EURbmy:customeriso4217:AUDbmy:acquirerbmy:claimbmy:healthcare_systembmy:plaintiffbmy:defendant00000142722024-01-012024-09-300000014272bmy:CommonStock0.10ParValueMember2024-01-012024-09-300000014272bmy:A1.000Notesdue2025Member2024-01-012024-09-300000014272bmy:A1.750Notesdue2035Member2024-01-012024-09-300000014272bmy:CelgeneContingentValueRightsMember2024-01-012024-09-3000000142722024-10-240000014272bmy:NetProductSalesMember2024-07-012024-09-300000014272bmy:NetProductSalesMember2023-07-012023-09-300000014272bmy:NetProductSalesMember2024-01-012024-09-300000014272bmy:NetProductSalesMember2023-01-012023-09-300000014272bmy:AllianceandotherrevenuesMember2024-07-012024-09-300000014272bmy:AllianceandotherrevenuesMember2023-07-012023-09-300000014272bmy:AllianceandotherrevenuesMember2024-01-012024-09-300000014272bmy:AllianceandotherrevenuesMember2023-01-012023-09-3000000142722024-07-012024-09-3000000142722023-07-012023-09-3000000142722023-01-012023-09-3000000142722024-09-3000000142722023-12-3100000142722022-12-3100000142722023-09-300000014272bmy:AllianceRevenuesMember2024-07-012024-09-300000014272bmy:AllianceRevenuesMember2023-07-012023-09-300000014272bmy:AllianceRevenuesMember2024-01-012024-09-300000014272bmy:AllianceRevenuesMember2023-01-012023-09-300000014272bmy:OtherRevenuesMember2024-07-012024-09-300000014272bmy:OtherRevenuesMember2023-07-012023-09-300000014272bmy:OtherRevenuesMember2024-01-012024-09-300000014272bmy:OtherRevenuesMember2023-01-012023-09-300000014272bmy:SalesRevenueGrossMember2024-07-012024-09-300000014272bmy:SalesRevenueGrossMember2023-07-012023-09-300000014272bmy:SalesRevenueGrossMember2024-01-012024-09-300000014272bmy:SalesRevenueGrossMember2023-01-012023-09-300000014272bmy:ChargebacksandcashdiscountsMember2024-07-012024-09-300000014272bmy:ChargebacksandcashdiscountsMember2023-07-012023-09-300000014272bmy:ChargebacksandcashdiscountsMember2024-01-012024-09-300000014272bmy:ChargebacksandcashdiscountsMember2023-01-012023-09-300000014272bmy:MedicaidandMedicarerebatesMember2024-07-012024-09-300000014272bmy:MedicaidandMedicarerebatesMember2023-07-012023-09-300000014272bmy:MedicaidandMedicarerebatesMember2024-01-012024-09-300000014272bmy:MedicaidandMedicarerebatesMember2023-01-012023-09-300000014272bmy:OtherrebatesreturnsdiscountsandadjustmentsMember2024-07-012024-09-300000014272bmy:OtherrebatesreturnsdiscountsandadjustmentsMember2023-07-012023-09-300000014272bmy:OtherrebatesreturnsdiscountsandadjustmentsMember2024-01-012024-09-300000014272bmy:OtherrebatesreturnsdiscountsandadjustmentsMember2023-01-012023-09-300000014272country:US2024-07-012024-09-300000014272country:US2024-01-012024-09-300000014272country:US2023-07-012023-09-300000014272country:US2023-01-012023-09-300000014272bmy:OpdivoMember2024-07-012024-09-300000014272bmy:OpdivoMember2023-07-012023-09-300000014272bmy:OpdivoMember2024-01-012024-09-300000014272bmy:OpdivoMember2023-01-012023-09-300000014272bmy:OrenciaMember2024-07-012024-09-300000014272bmy:OrenciaMember2023-07-012023-09-300000014272bmy:OrenciaMember2024-01-012024-09-300000014272bmy:OrenciaMember2023-01-012023-09-300000014272bmy:YervoyMember2024-07-012024-09-300000014272bmy:YervoyMember2023-07-012023-09-300000014272bmy:YervoyMember2024-01-012024-09-300000014272bmy:YervoyMember2023-01-012023-09-300000014272bmy:ReblozylMember2024-07-012024-09-300000014272bmy:ReblozylMember2023-07-012023-09-300000014272bmy:ReblozylMember2024-01-012024-09-300000014272bmy:ReblozylMember2023-01-012023-09-300000014272bmy:OpdualagMember2024-07-012024-09-300000014272bmy:OpdualagMember2023-07-012023-09-300000014272bmy:OpdualagMember2024-01-012024-09-300000014272bmy:OpdualagMember2023-01-012023-09-300000014272bmy:AbecmaMember2024-07-012024-09-300000014272bmy:AbecmaMember2023-07-012023-09-300000014272bmy:AbecmaMember2024-01-012024-09-300000014272bmy:AbecmaMember2023-01-012023-09-300000014272bmy:ZeposiaMember2024-07-012024-09-300000014272bmy:ZeposiaMember2023-07-012023-09-300000014272bmy:ZeposiaMember2024-01-012024-09-300000014272bmy:ZeposiaMember2023-01-012023-09-300000014272bmy:BreyanziMember2024-07-012024-09-300000014272bmy:BreyanziMember2023-07-012023-09-300000014272bmy:BreyanziMember2024-01-012024-09-300000014272bmy:BreyanziMember2023-01-012023-09-300000014272bmy:CamzyosMember2024-07-012024-09-300000014272bmy:CamzyosMember2023-07-012023-09-300000014272bmy:CamzyosMember2024-01-012024-09-300000014272bmy:CamzyosMember2023-01-012023-09-300000014272bmy:SotyktuMember2024-07-012024-09-300000014272bmy:SotyktuMember2023-07-012023-09-300000014272bmy:SotyktuMember2024-01-012024-09-300000014272bmy:SotyktuMember2023-01-012023-09-300000014272bmy:AugtyroMember2024-07-012024-09-300000014272bmy:AugtyroMember2023-07-012023-09-300000014272bmy:AugtyroMember2024-01-012024-09-300000014272bmy:AugtyroMember2023-01-012023-09-300000014272bmy:KrazatiMember2024-07-012024-09-300000014272bmy:KrazatiMember2023-07-012023-09-300000014272bmy:KrazatiMember2024-01-012024-09-300000014272bmy:KrazatiMember2023-01-012023-09-300000014272bmy:OtherGrowthBrandsMember2024-07-012024-09-300000014272bmy:OtherGrowthBrandsMember2023-07-012023-09-300000014272bmy:OtherGrowthBrandsMember2024-01-012024-09-300000014272bmy:OtherGrowthBrandsMember2023-01-012023-09-300000014272bmy:GrowthBrandsMember2024-07-012024-09-300000014272bmy:GrowthBrandsMember2023-07-012023-09-300000014272bmy:GrowthBrandsMember2024-01-012024-09-300000014272bmy:GrowthBrandsMember2023-01-012023-09-300000014272bmy:EliquisMember2024-07-012024-09-300000014272bmy:EliquisMember2023-07-012023-09-300000014272bmy:EliquisMember2024-01-012024-09-300000014272bmy:EliquisMember2023-01-012023-09-300000014272bmy:RevlimidMember2024-07-012024-09-300000014272bmy:RevlimidMember2023-07-012023-09-300000014272bmy:RevlimidMember2024-01-012024-09-300000014272bmy:RevlimidMember2023-01-012023-09-300000014272bmy:PomalystImnovidMember2024-07-012024-09-300000014272bmy:PomalystImnovidMember2023-07-012023-09-300000014272bmy:PomalystImnovidMember2024-01-012024-09-300000014272bmy:PomalystImnovidMember2023-01-012023-09-300000014272bmy:SprycelMember2024-07-012024-09-300000014272bmy:SprycelMember2023-07-012023-09-300000014272bmy:SprycelMember2024-01-012024-09-300000014272bmy:SprycelMember2023-01-012023-09-300000014272bmy:AbraxaneMember2024-07-012024-09-300000014272bmy:AbraxaneMember2023-07-012023-09-300000014272bmy:AbraxaneMember2024-01-012024-09-300000014272bmy:AbraxaneMember2023-01-012023-09-300000014272bmy:OtherLegacyBrandsMember2024-07-012024-09-300000014272bmy:OtherLegacyBrandsMember2023-07-012023-09-300000014272bmy:OtherLegacyBrandsMember2024-01-012024-09-300000014272bmy:OtherLegacyBrandsMember2023-01-012023-09-300000014272bmy:LegacyBrandsMember2024-07-012024-09-300000014272bmy:LegacyBrandsMember2023-07-012023-09-300000014272bmy:LegacyBrandsMember2024-01-012024-09-300000014272bmy:LegacyBrandsMember2023-01-012023-09-300000014272bmy:InternationalMember2024-07-012024-09-300000014272bmy:InternationalMember2023-07-012023-09-300000014272bmy:InternationalMember2024-01-012024-09-300000014272bmy:InternationalMember2023-01-012023-09-300000014272bmy:OtherRegionMember2024-07-012024-09-300000014272bmy:OtherRegionMember2023-07-012023-09-300000014272bmy:OtherRegionMember2024-01-012024-09-300000014272bmy:OtherRegionMember2023-01-012023-09-300000014272bmy:NetProductSalesMemberus-gaap:CollaborativeArrangementMember2024-07-012024-09-300000014272bmy:NetProductSalesMemberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300000014272bmy:NetProductSalesMemberus-gaap:CollaborativeArrangementMember2024-01-012024-09-300000014272bmy:NetProductSalesMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300000014272us-gaap:CollaborativeArrangementMember2024-07-012024-09-300000014272us-gaap:CollaborativeArrangementMember2023-07-012023-09-300000014272us-gaap:CollaborativeArrangementMember2024-01-012024-09-300000014272us-gaap:CollaborativeArrangementMember2023-01-012023-09-300000014272us-gaap:CollaborativeArrangementMember2024-09-300000014272us-gaap:CollaborativeArrangementMember2023-12-310000014272bmy:SystImmuneMember2024-01-012024-09-300000014272bmy:EisaiMember2024-01-012024-09-300000014272bmy:EisaiMember2024-07-012024-09-300000014272bmy:KarunaMember2024-03-180000014272bmy:KarunaMember2024-03-182024-03-180000014272bmy:AcquiredIPRDMemberbmy:KarunaMember2024-01-012024-09-300000014272us-gaap:CommonStockMemberbmy:KarunaMember2024-03-182024-03-180000014272us-gaap:EquityMemberbmy:KarunaMember2024-03-182024-03-180000014272bmy:UnvestedEquityAwardsMemberbmy:KarunaMember2024-03-182024-03-180000014272us-gaap:InProcessResearchAndDevelopmentMemberbmy:KarunaMember2024-03-182024-03-180000014272bmy:UnvestedEquityAwardsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberbmy:KarunaMember2024-01-012024-09-300000014272bmy:UnvestedEquityAwardsMemberus-gaap:ResearchAndDevelopmentExpenseMemberbmy:KarunaMember2024-01-012024-09-300000014272bmy:RayzeBioMember2024-02-260000014272bmy:RayzeBioMember2024-02-262024-02-260000014272us-gaap:CommonStockMemberbmy:RayzeBioMember2024-02-262024-02-260000014272us-gaap:EquityMemberbmy:RayzeBioMember2024-02-262024-02-260000014272bmy:UnvestedEquityAwardsMemberbmy:RayzeBioMember2024-02-262024-02-260000014272bmy:RayzeBioMemberbmy:UnvestedEquityAwardsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000014272bmy:RayzeBioMemberbmy:UnvestedEquityAwardsMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000014272bmy:RayzeBioMemberus-gaap:InProcessResearchAndDevelopmentMember2024-02-260000014272bmy:RayzeBioMemberus-gaap:DevelopedTechnologyRightsMember2024-02-260000014272bmy:MiratiTherapeuticsMember2024-01-230000014272bmy:MiratiTherapeuticsMember2024-01-232024-01-2300000142722024-01-230000014272us-gaap:CommonStockMemberbmy:MiratiTherapeuticsMember2024-01-232024-01-230000014272us-gaap:EquityMemberbmy:MiratiTherapeuticsMember2024-01-232024-01-230000014272bmy:UnvestedEquityAwardsMemberbmy:MiratiTherapeuticsMember2024-01-232024-01-230000014272bmy:MiratiTherapeuticsMemberbmy:UnvestedEquityAwardsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000014272bmy:MiratiTherapeuticsMemberbmy:UnvestedEquityAwardsMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000014272bmy:InventoryPurchasePriceFairValueAdjustmentMember2024-01-230000014272bmy:MiratiTherapeuticsMemberbmy:AcquiredMarketedProductRightsMember2024-01-230000014272bmy:MiratiTherapeuticsMemberus-gaap:InProcessResearchAndDevelopmentMember2024-01-230000014272bmy:DiabetesBusinessMember2024-07-012024-09-300000014272bmy:DiabetesBusinessMember2023-07-012023-09-300000014272bmy:MatureBrandsAndOtherMember2024-07-012024-09-300000014272bmy:MatureBrandsAndOtherMember2023-07-012023-09-300000014272bmy:DiabetesBusinessMember2024-01-012024-09-300000014272bmy:DiabetesBusinessMember2023-01-012023-09-300000014272bmy:MatureBrandsAndOtherMember2024-01-012024-09-300000014272bmy:MatureBrandsAndOtherMember2023-01-012023-09-300000014272bmy:KeytrudaRoyaltiesMember2024-07-012024-09-300000014272bmy:KeytrudaRoyaltiesMember2023-07-012023-09-300000014272bmy:KeytrudaRoyaltiesMember2024-01-012024-09-300000014272bmy:KeytrudaRoyaltiesMember2023-01-012023-09-300000014272bmy:TecentriqRoyaltiesMember2024-07-012024-09-300000014272bmy:TecentriqRoyaltiesMember2023-07-012023-09-300000014272bmy:TecentriqRoyaltiesMember2024-01-012024-09-300000014272bmy:TecentriqRoyaltiesMember2023-01-012023-09-300000014272bmy:OtherRoyaltiesAndLicensingIncomeMember2024-07-012024-09-300000014272bmy:OtherRoyaltiesAndLicensingIncomeMember2023-07-012023-09-300000014272bmy:OtherRoyaltiesAndLicensingIncomeMember2024-01-012024-09-300000014272bmy:OtherRoyaltiesAndLicensingIncomeMember2023-01-012023-09-300000014272bmy:KeytrudaRoyaltiesMember2023-01-012023-12-310000014272bmy:KeytrudaRoyaltiesMembersrt:ScenarioForecastMember2024-01-012026-12-310000014272bmy:KeytrudaRoyaltiesMemberbmy:BristolMyersSquibbMembersrt:ScenarioForecastMember2024-01-012026-12-310000014272bmy:KeytrudaRoyaltiesMemberbmy:OnoMembersrt:ScenarioForecastMember2024-01-012026-12-310000014272us-gaap:OtherIncomeMember2024-07-012024-09-300000014272us-gaap:OtherIncomeMember2023-07-012023-09-300000014272us-gaap:OtherIncomeMember2024-01-012024-09-300000014272us-gaap:OtherIncomeMember2023-01-012023-09-300000014272bmy:NimbusTherapueticsTYK2InhibitorMember2023-01-012023-09-300000014272bmy:BeiGeneMember2023-08-310000014272bmy:BeiGeneMember2023-07-012023-09-300000014272bmy:BeiGeneMember2023-01-012023-09-300000014272bmy:AZABMember2023-07-310000014272bmy:AZABMembersrt:ScenarioForecastMember2023-07-312026-09-300000014272bmy:AZABMember2024-07-012024-09-300000014272bmy:AZABMember2024-01-012024-09-300000014272bmy:A2023RestructuringPlanMember2024-09-300000014272bmy:CelgeneAndOtherAcquisitionPlansMember2024-09-300000014272bmy:A2023RestructuringPlanMember2024-07-012024-09-300000014272bmy:A2023RestructuringPlanMember2023-07-012023-09-300000014272bmy:A2023RestructuringPlanMember2024-01-012024-09-300000014272bmy:A2023RestructuringPlanMember2023-01-012023-09-300000014272bmy:CelgeneAndOtherAcquisitionPlansMember2024-07-012024-09-300000014272bmy:CelgeneAndOtherAcquisitionPlansMember2023-07-012023-09-300000014272bmy:CelgeneAndOtherAcquisitionPlansMember2024-01-012024-09-300000014272bmy:CelgeneAndOtherAcquisitionPlansMember2023-01-012023-09-300000014272bmy:OtherTerminationCostsMember2024-07-012024-09-300000014272bmy:OtherTerminationCostsMember2023-07-012023-09-300000014272bmy:OtherTerminationCostsMember2024-01-012024-09-300000014272bmy:OtherTerminationCostsMember2023-01-012023-09-300000014272bmy:OtherShutdownCostsMember2024-07-012024-09-300000014272bmy:OtherShutdownCostsMember2023-07-012023-09-300000014272bmy:OtherShutdownCostsMember2024-01-012024-09-300000014272bmy:OtherShutdownCostsMember2023-01-012023-09-300000014272us-gaap:CostOfSalesMember2024-07-012024-09-300000014272us-gaap:CostOfSalesMember2023-07-012023-09-300000014272us-gaap:CostOfSalesMember2024-01-012024-09-300000014272us-gaap:CostOfSalesMember2023-01-012023-09-300000014272us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300000014272us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000014272us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000014272us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000014272us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000014272us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000014272us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000014272us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000014272us-gaap:OtherNonoperatingIncomeExpenseMember2024-07-012024-09-300000014272us-gaap:OtherNonoperatingIncomeExpenseMember2023-07-012023-09-300000014272us-gaap:OtherNonoperatingIncomeExpenseMember2024-01-012024-09-300000014272us-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-09-300000014272bmy:SiteImpairmentMember2024-07-012024-09-300000014272us-gaap:FacilityClosingMember2023-07-012023-09-300000014272srt:MinimumMember2024-09-300000014272srt:MaximumMember2024-09-300000014272us-gaap:FairValueInputsLevel1Member2024-09-300000014272us-gaap:FairValueInputsLevel2Member2024-09-300000014272us-gaap:FairValueInputsLevel3Member2024-09-300000014272us-gaap:FairValueInputsLevel1Member2023-12-310000014272us-gaap:FairValueInputsLevel2Member2023-12-310000014272us-gaap:FairValueInputsLevel3Member2023-12-310000014272us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2024-09-300000014272us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2024-09-300000014272us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2024-09-300000014272us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2023-12-310000014272us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2023-12-310000014272us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2023-12-310000014272us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2024-09-300000014272us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-09-300000014272us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2024-09-300000014272us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2023-12-310000014272us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310000014272us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2023-12-310000014272us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300000014272us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300000014272us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300000014272us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000014272us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000014272us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000014272us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2024-09-300000014272us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-09-300000014272us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2024-09-300000014272us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-12-310000014272us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310000014272us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2023-12-310000014272us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMember2024-09-300000014272us-gaap:FairValueInputsLevel2Memberus-gaap:OtherAssetsMember2024-09-300000014272us-gaap:FairValueInputsLevel3Memberus-gaap:OtherAssetsMember2024-09-300000014272us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMember2023-12-310000014272us-gaap:FairValueInputsLevel2Memberus-gaap:OtherAssetsMember2023-12-310000014272us-gaap:FairValueInputsLevel3Memberus-gaap:OtherAssetsMember2023-12-310000014272bmy:ContingentValueRightsMemberus-gaap:FairValueInputsLevel1Member2024-09-300000014272bmy:ContingentValueRightsMemberus-gaap:FairValueInputsLevel2Member2024-09-300000014272bmy:ContingentValueRightsMemberus-gaap:FairValueInputsLevel3Member2024-09-300000014272bmy:ContingentValueRightsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000014272bmy:ContingentValueRightsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000014272bmy:ContingentValueRightsMemberus-gaap:FairValueInputsLevel3Member2023-12-310000014272us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-09-300000014272us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPY2024-09-300000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000014272us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-01-310000014272us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-01-310000014272bmy:CrossCurrencyInterestRateAndForeignCurrencyForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000014272bmy:CrossCurrencyInterestRateAndForeignCurrencyForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPY2024-09-300000014272bmy:CrossCurrencyInterestRateAndForeignCurrencyForwardContractsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-09-300000014272us-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2023-12-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2023-12-310000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2024-09-300000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2024-09-300000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2023-12-310000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2023-12-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2023-12-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2023-12-310000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2024-09-300000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2024-09-300000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2023-12-310000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000014272us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2023-12-310000014272us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2024-09-300000014272us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000014272us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2024-09-300000014272us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AssetsMember2023-12-310000014272us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000014272us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LiabilityMember2023-12-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:AssetsMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:LiabilityMember2024-09-300000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:AssetsMember2023-12-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-12-310000014272us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:LiabilityMember2023-12-310000014272us-gaap:OtherContractMemberus-gaap:NondesignatedMemberus-gaap:AssetsMember2024-09-300000014272us-gaap:OtherContractMemberus-gaap:NondesignatedMember2024-09-300000014272us-gaap:OtherContractMemberus-gaap:NondesignatedMemberus-gaap:LiabilityMember2024-09-300000014272us-gaap:OtherContractMemberus-gaap:NondesignatedMemberus-gaap:AssetsMember2023-12-310000014272us-gaap:OtherContractMemberus-gaap:NondesignatedMember2023-12-310000014272us-gaap:OtherContractMemberus-gaap:NondesignatedMemberus-gaap:LiabilityMember2023-12-310000014272us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMember2024-07-012024-09-300000014272us-gaap:OtherIncomeMemberus-gaap:ForeignExchangeForwardMember2024-07-012024-09-300000014272us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-09-300000014272us-gaap:OtherIncomeMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-09-300000014272us-gaap:CostOfSalesMemberus-gaap:CrossCurrencyInterestRateContractMember2024-07-012024-09-300000014272us-gaap:OtherIncomeMemberus-gaap:CrossCurrencyInterestRateContractMember2024-07-012024-09-300000014272us-gaap:CostOfSalesMemberus-gaap:CrossCurrencyInterestRateContractMember2024-01-012024-09-300000014272us-gaap:OtherIncomeMemberus-gaap:CrossCurrencyInterestRateContractMember2024-01-012024-09-300000014272us-gaap:CostOfSalesMemberus-gaap:InterestRateSwapMember2024-07-012024-09-300000014272us-gaap:OtherIncomeMemberus-gaap:InterestRateSwapMember2024-07-012024-09-300000014272us-gaap:CostOfSalesMemberus-gaap:InterestRateSwapMember2024-01-012024-09-300000014272us-gaap:OtherIncomeMemberus-gaap:InterestRateSwapMember2024-01-012024-09-300000014272us-gaap:CostOfSalesMemberus-gaap:InterestRateContractMember2024-07-012024-09-300000014272us-gaap:OtherIncomeMemberus-gaap:InterestRateContractMember2024-07-012024-09-300000014272us-gaap:CostOfSalesMemberus-gaap:InterestRateContractMember2024-01-012024-09-300000014272us-gaap:OtherIncomeMemberus-gaap:InterestRateContractMember2024-01-012024-09-300000014272us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMember2023-07-012023-09-300000014272us-gaap:OtherIncomeMemberus-gaap:ForeignExchangeForwardMember2023-07-012023-09-300000014272us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000014272us-gaap:OtherIncomeMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000014272us-gaap:CostOfSalesMemberus-gaap:CrossCurrencyInterestRateContractMember2023-07-012023-09-300000014272us-gaap:OtherIncomeMemberus-gaap:CrossCurrencyInterestRateContractMember2023-07-012023-09-300000014272us-gaap:CostOfSalesMemberus-gaap:CrossCurrencyInterestRateContractMember2023-01-012023-09-300000014272us-gaap:OtherIncomeMemberus-gaap:CrossCurrencyInterestRateContractMember2023-01-012023-09-300000014272us-gaap:CostOfSalesMemberus-gaap:InterestRateSwapMember2023-07-012023-09-300000014272us-gaap:OtherIncomeMemberus-gaap:InterestRateSwapMember2023-07-012023-09-300000014272us-gaap:CostOfSalesMemberus-gaap:InterestRateSwapMember2023-01-012023-09-300000014272us-gaap:OtherIncomeMemberus-gaap:InterestRateSwapMember2023-01-012023-09-300000014272us-gaap:ForeignExchangeForwardMember2024-07-012024-09-300000014272us-gaap:ForeignExchangeForwardMember2023-07-012023-09-300000014272us-gaap:ForeignExchangeForwardMember2024-01-012024-09-300000014272us-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000014272us-gaap:CrossCurrencyInterestRateContractMember2024-07-012024-09-300000014272us-gaap:CrossCurrencyInterestRateContractMember2023-07-012023-09-300000014272us-gaap:CrossCurrencyInterestRateContractMember2024-01-012024-09-300000014272us-gaap:CrossCurrencyInterestRateContractMember2023-01-012023-09-300000014272us-gaap:InterestRateSwapMember2024-07-012024-09-300000014272us-gaap:InterestRateSwapMember2023-07-012023-09-300000014272us-gaap:InterestRateSwapMember2024-01-012024-09-300000014272us-gaap:InterestRateSwapMember2023-01-012023-09-300000014272us-gaap:OtherOperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2024-07-012024-09-300000014272us-gaap:OtherOperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2023-07-012023-09-300000014272us-gaap:OtherOperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2024-01-012024-09-300000014272us-gaap:OtherOperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2023-01-012023-09-300000014272us-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000014272us-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000014272us-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300000014272us-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300000014272bmy:CommercialPaperProgramMemberus-gaap:CommercialPaperMember2024-09-300000014272bmy:CommercialPaperProgramMemberus-gaap:CommercialPaperMember2024-01-012024-09-3000000142722024-01-012024-03-310000014272us-gaap:InterestRateSwapMember2024-09-300000014272us-gaap:InterestRateSwapMember2023-12-310000014272bmy:A2024SeniorUnsecuredNotesMember2024-03-310000014272bmy:FloatingRateNotesDue2026Member2024-03-310000014272bmy:A4.950NotesDue2026Member2024-03-310000014272bmy:A4.900NotesDue2027Member2024-03-310000014272bmy:A4.900NotesDue2029Member2024-03-310000014272bmy:A5.100NotesDue2031Member2024-03-310000014272bmy:A5.200NotesDue2034Member2024-03-310000014272bmy:A5.500NotesDue2044Member2024-03-310000014272bmy:A5.550NotesDue2054Member2024-03-310000014272bmy:A5.650NotesDue2064Member2024-03-310000014272us-gaap:UnsecuredDebtMemberus-gaap:LineOfCreditMember2024-02-290000014272us-gaap:UnsecuredDebtMemberus-gaap:LineOfCreditMember2024-02-012024-02-290000014272bmy:A2.900NotesMember2024-01-012024-09-300000014272bmy:A2.900NotesMember2024-09-300000014272bmy:A3.625NotesMember2024-01-012024-09-300000014272bmy:A3.625NotesMember2024-09-300000014272bmy:A2750NotesMember2023-01-012023-09-300000014272bmy:A2750NotesMember2023-09-300000014272bmy:A3250NotesMember2023-01-012023-09-300000014272bmy:A3250NotesMember2023-09-300000014272bmy:A7150NotesMember2023-01-012023-09-300000014272bmy:A7150NotesMember2023-09-300000014272bmy:A5BillionMaximumBorrowingCapacityMember2024-09-300000014272bmy:A2BillionMaximumBorrowingCapacityMember2024-09-300000014272us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310000014272us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300000014272us-gaap:CustomerConcentrationRiskMember2024-09-300000014272us-gaap:CustomerConcentrationRiskMember2023-12-310000014272us-gaap:TechnologyBasedIntangibleAssetsMember2024-09-300000014272us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000014272bmy:AcquiredMarketedProductRightsMembersrt:MinimumMember2024-09-300000014272bmy:AcquiredMarketedProductRightsMembersrt:MaximumMember2024-09-300000014272bmy:AcquiredMarketedProductRightsMember2024-09-300000014272bmy:AcquiredMarketedProductRightsMember2023-12-310000014272us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MinimumMember2024-09-300000014272us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MaximumMember2024-09-300000014272us-gaap:ComputerSoftwareIntangibleAssetMember2024-09-300000014272us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310000014272us-gaap:InProcessResearchAndDevelopmentMember2024-09-300000014272us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000014272bmy:CostsOfGoodsSoldMember2024-07-012024-09-300000014272bmy:CostsOfGoodsSoldMember2023-07-012023-09-300000014272bmy:CostsOfGoodsSoldMember2024-01-012024-09-300000014272bmy:CostsOfGoodsSoldMember2023-01-012023-09-300000014272bmy:OtherResearchAndDevelopmentMember2024-07-012024-09-300000014272bmy:OtherResearchAndDevelopmentMember2023-07-012023-09-300000014272bmy:OtherResearchAndDevelopmentMember2024-01-012024-09-300000014272bmy:OtherResearchAndDevelopmentMember2023-01-012023-09-300000014272us-gaap:OtherIncomeMember2024-07-012024-09-300000014272us-gaap:OtherIncomeMember2023-07-012023-09-300000014272us-gaap:OtherIncomeMember2024-01-012024-09-300000014272us-gaap:OtherIncomeMember2023-01-012023-09-300000014272us-gaap:CommonStockMember2023-12-310000014272us-gaap:AdditionalPaidInCapitalMember2023-12-310000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000014272us-gaap:RetainedEarningsMember2023-12-310000014272us-gaap:TreasuryStockCommonMember2023-12-310000014272us-gaap:NoncontrollingInterestMember2023-12-310000014272us-gaap:RetainedEarningsMember2024-01-012024-03-310000014272us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000014272us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000014272us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000014272us-gaap:CommonStockMember2024-03-310000014272us-gaap:AdditionalPaidInCapitalMember2024-03-310000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000014272us-gaap:RetainedEarningsMember2024-03-310000014272us-gaap:TreasuryStockCommonMember2024-03-310000014272us-gaap:NoncontrollingInterestMember2024-03-310000014272us-gaap:RetainedEarningsMember2024-04-012024-06-300000014272us-gaap:NoncontrollingInterestMember2024-04-012024-06-300000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-3000000142722024-04-012024-06-300000014272us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000014272us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000014272us-gaap:CommonStockMember2024-06-300000014272us-gaap:AdditionalPaidInCapitalMember2024-06-300000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000014272us-gaap:RetainedEarningsMember2024-06-300000014272us-gaap:TreasuryStockCommonMember2024-06-300000014272us-gaap:NoncontrollingInterestMember2024-06-300000014272us-gaap:RetainedEarningsMember2024-07-012024-09-300000014272us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000014272us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000014272us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000014272us-gaap:CommonStockMember2024-09-300000014272us-gaap:AdditionalPaidInCapitalMember2024-09-300000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000014272us-gaap:RetainedEarningsMember2024-09-300000014272us-gaap:TreasuryStockCommonMember2024-09-300000014272us-gaap:NoncontrollingInterestMember2024-09-300000014272us-gaap:CommonStockMember2022-12-310000014272us-gaap:AdditionalPaidInCapitalMember2022-12-310000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000014272us-gaap:RetainedEarningsMember2022-12-310000014272us-gaap:TreasuryStockCommonMember2022-12-310000014272us-gaap:NoncontrollingInterestMember2022-12-310000014272us-gaap:RetainedEarningsMember2023-01-012023-03-310000014272us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-3100000142722023-01-012023-03-310000014272us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000014272us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000014272us-gaap:CommonStockMember2023-03-310000014272us-gaap:AdditionalPaidInCapitalMember2023-03-310000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000014272us-gaap:RetainedEarningsMember2023-03-310000014272us-gaap:TreasuryStockCommonMember2023-03-310000014272us-gaap:NoncontrollingInterestMember2023-03-310000014272us-gaap:RetainedEarningsMember2023-04-012023-06-300000014272us-gaap:NoncontrollingInterestMember2023-04-012023-06-300000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000000142722023-04-012023-06-300000014272us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000014272us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000014272us-gaap:CommonStockMember2023-06-300000014272us-gaap:AdditionalPaidInCapitalMember2023-06-300000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000014272us-gaap:RetainedEarningsMember2023-06-300000014272us-gaap:TreasuryStockCommonMember2023-06-300000014272us-gaap:NoncontrollingInterestMember2023-06-300000014272us-gaap:RetainedEarningsMember2023-07-012023-09-300000014272us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000014272us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000014272us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000014272us-gaap:CommonStockMember2023-09-300000014272us-gaap:AdditionalPaidInCapitalMember2023-09-300000014272us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000014272us-gaap:RetainedEarningsMember2023-09-300000014272us-gaap:TreasuryStockCommonMember2023-09-300000014272us-gaap:NoncontrollingInterestMember2023-09-300000014272bmy:A2023ASRMember2023-09-300000014272bmy:A2023ASRMember2023-07-012023-09-300000014272bmy:ShareRepurchaseProgramMember2023-07-012023-09-300000014272us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000014272bmy:MarketShareUnitsMember2024-01-012024-09-300000014272us-gaap:PerformanceSharesMember2024-01-012024-09-300000014272us-gaap:RestrictedStockUnitsRSUMember2024-09-300000014272bmy:MarketShareUnitsMember2024-09-300000014272us-gaap:PerformanceSharesMember2024-09-300000014272bmy:PlavixAustraliaIntellectualPropertyMember2010-03-012010-03-3100000142722021-02-012021-02-280000014272bmy:BristolMyersSquibbMember2021-02-012021-02-2800000142722024-05-212024-05-210000014272bmy:BristolMyersSquibbMember2024-05-212024-05-210000014272bmy:AbilifyProductLiabilityMemberstpr:NJ2024-09-300000014272bmy:AbilifyProductLiabilityMembercountry:CA2024-09-300000014272bmy:CelgeneSecuritiesClassActionMember2018-03-3100000142722021-06-300000014272bmy:CelgeneContingentValueRightsMember2021-11-300000014272bmy:MolinaLitigationMember2022-06-300000014272bmy:OptOutEntitiesMember2024-09-3000000142722022-11-3000000142722023-10-012023-11-300000014272bmy:MayoClinicLifePointCorporateServicesAndIntermountainHealthMember2023-11-300000014272bmy:PomalystAntitrustClassActionMember2023-12-012023-12-310000014272bmy:PomalystAntitrustClassActionMember2024-03-012024-03-31



美國
證券交易委員會
華盛頓特區20549
___________________________
表格 10-Q
___________________________
☒ 根據《證券交易法》第13或15(d)條規定提交的季度報告書
證券交易所法案(1934年)
截至季度結束日期的財務報告2024年9月30日
或者
☐ 根據《證券交易法》第13或15(d)條規定提交的過渡報告書
證券交易所法案(1934年)
過渡期從________到________
委員會文件號 001-01136
___________________________
施貴寶公司
(根據其章程規定的註冊人準確名稱)
___________________________
特拉華州 22-0790350
（國家或其他管轄區的
公司成立或組織）		 
(國稅局 僱主
唯一識別號碼）
206路和省界路口, 普林斯頓, 新澤西州。 08543
（總部地址）（郵政編碼）
(609) 252-4621
(公司電話號碼，包括區號)

___________________________
（前名稱、地址及財政年度，如果自上次報告以來有更改）

在法案第12(b)條的規定下注冊的證券：
每一類的名稱交易標誌在其上註冊的交易所的名稱
普通股，每股面值$0.10BMY請使用moomoo賬號登錄查看New York Stock Exchange
1.000％ Notes due 2025BMY25請使用moomoo賬號登錄查看New York Stock Exchange
2035年到期的1.750%票據BMY35請使用moomoo賬號登錄查看New York Stock Exchange
Celgene的權益交易CELG RT請使用moomoo賬號登錄查看New York Stock Exchange
請勾選表示註冊人已在過去12個月內(或註冊人被要求提交此類報告的更短期限內)根據1934年證券交易法第13或15(d)條的要求提交了所有報告，並且在過去90天內一直受到提交要求的約束。是  ☒沒有☐
請勾選以下內容。申報人是否已在過去12個月內（或申報人需要提交此類文件的時間較短的期間內）逐個以電子方式提交了根據規則405提交的互動數據文件。這章的交易中規定。    是  ☒    否  ☐
請通過勾選符號來指示註冊人是大型加速文件提交者，加速文件提交者，非加速文件提交者，小型報告公司還是新興成長型公司。請參閱「定義」部分大型加速文件提交者，《交易所法》第120億.2條中「大型加速報告人」、「加速報告人」、「小型報表公司」和「新興成長公司」的定義。
大型加速交易者☒
加快推進者☐
非加速股票交易所申報人☐
小型報告公司  ☐
新興成長公司☐
如果是新興成長型公司，請勾選是否已選擇不使用根據交易所法案第13(a)條款提供的任何新的或修訂的財務會計準則的延長過渡期來遵守。 ☐
請用勾號標註是否註冊申報人爲殼公司（如《交易所法》第120億.2條所定義）。是 ☐ 否☒
僅適用於公司發行人：
2024年10月24日，有 2,028,176,674 註冊公司每股面值爲0.10美元的普通股。





施貴寶公司
10-Q表格索引
2024年9月30日
第一部分——財務信息
項目1。
項目2。
項目3。
項目4。
第二部分-其他信息
項目1。
項目1A。
項目2。
項目5。
項目6。
*  指示不屬於bms系統擁有的商標的產品品牌名稱。具體的商標所有權信息在本季度報告的表格指數中包含。



第一部分——財務信息

第1條 基本報表
施貴寶公司
2020年11月1日
以百萬美元爲單位，除每股數據外
(未經審計)

 截至9月30日的三個月截至9月30日的九個月
已實收資本2024202320242023
產品淨銷售額$11,483 $10,645 $34,967 $32,610 
聯盟及其他收入409 321 991 919 
總營收11,892 10,966 35,958 33,529 
銷售產品成本(a)
2,957 2,506 9,156 7,948 
營銷、銷售和行政1,983 2,003 6,278 5,699 
研發2,374 2,242 7,968 6,821 
Acquired IPRD262 80 13,343 313 
取得的無形資產攤銷2,406 2,256 7,179 6,769 
其他收入/費用，淨額
234 (258)588 (787)
總費用10,216 8,829 44,512 26,763 
稅前收益/(損失)
1,676 2,137 (8,554)6,766 
所得稅費用
461 203 455 488 
淨收益/(虧損)
1,215 1,934 (9,009)6,278 
非控股權益4 6 11 15 
歸屬bms系統的淨收益/(虧損)
$1,211 $1,928 $(9,020)$6,263 
每股普通股收益/(虧損):
基本$0.60 $0.94 $(4.45)$3.01 
稀釋的0.60 0.93 (4.45)2.99 
(a)    不包括已取得無形資產的攤銷.


綜合收益（損失）表
美元數百萬
(未經審計)
 截至9月30日的三個月截至9月30日的九個月
未經審計的簡要合併損益表和綜合收益表
2024202320242023
淨收益/(虧損)
$1,215 $1,934 $(9,009)$6,278 
其他全面收益/(損失)，淨額，稅後和重新分類至收益:
符合現金流量套期交易條件的衍生品(178)114 67 (7)
養老金和離退休福利100 2 49 (9)
有價證券5 (2)3 (2)
外幣翻譯61 (13)(41)13 
其他綜合收益/(損失)(12)101 78 (5)
綜合收益/(損失)
1,203 2,035 (8,931)6,273 
歸屬於非控股股東的綜合收益4 6 11 15 
歸屬於bms系統的綜合收益/(損失)
$1,199 $2,029 $(8,942)$6,258 
附註是這些合併財務報表的一部分。

3

施貴寶公司
基本報表
美元數百萬
(未經審計)
 
資產2020年9月30日
2024		12月31日
2023
流動資產：
現金及現金等價物$7,890 $11,464 
有價證券204 816 
應收賬款11,026 10,921 
存貨3,332 2,662 
其他資產5,623 5,907 
當前總資產28,075 31,770 
資產：固定資產6,903 6,646 
商譽21,751 21,169 
其他無形資產26,964 27,072 
延遲所得稅3,609 2,768 
有市場的債務證券
324 364 
其他非流動資產6,044 5,370 
總資產$93,670 $95,159 
負債
流動負債:
短期債務$1,078 $3,119 
應付賬款3,469 3,259 
其他流動負債18,091 15,884 
所有流動負債總計22,638 22,262 
延遲所得稅430 338 
長期債務48,674 36,653 
其他非流動負債4,728 6,421 
總負債76,470 65,674 
承諾和事後約定
股東權益
bms系統股東權益:
優先股— — 
292 292 
超過股票面值的資本45,896 45,684 
累計其他綜合損失(1,468)(1,546)
保留盈餘16,097 28,766 
財務開空股本成本(43,675)(43,766)
bms系統股東權益合計17,142 29,430 
非控股權益58 55 
總股本17,200 29,485 
總負債和股權$93,670 $95,159 
附註是這些合併財務報表的一部分。
4


施貴寶公司
綜合現金流量表
美元數百萬
(未經審計)
 截至9月30日的九個月
 20242023
經營活動產生的現金流量：
淨收益/(損失)
$(9,009)$6,278 
調整以按應計利息法計算的淨收益至經營性現金流量的調整項：
折舊和攤銷淨額7,720 7,296 
延遲所得稅(1,298)(1,961)
以股票爲基礎的報酬計劃387 391 
減值損失1,010 226 
資產剝離收益和特許權使用費(838)(639)
Acquired IPRD13,343 313 
股權投資收益/損失
(221)213 
其他調整123 260 
經營性資產和負債變動:
應收賬款121 (487)
存貨(661)(554)
應付賬款(333)(246)
回扣和折扣1,889 1,115 
應付所得稅(1,381)(1,647)
其他(101)(950)
經營活動產生的現金流量淨額10,751 9,608 
投資活動現金流量:
可交易債務證券的銷售和到期1,060 692 
有價證券的購買(398)(1,057)
出售股權投資的收益60 215 
資本支出(870)(879)
剝離和其他收入766 668 
收購和其他支付，扣除獲得的現金淨額(21,774)(588)
投資活動產生的淨現金流出(21,156)(949)
籌資活動現金流量:
短期債務發行收益
2,987 — 
短期債務償還
(3,000)— 
其他短期融資義務淨額
504 233 
長期債務發行所得
12,883 — 
長期負債還款
(2,873)(1,879)
回購普通股— (5,155)
股息(3,645)(3,584)
股票期權的收益和其他，淨值(87)2 
融資活動產生的現金流量淨額
6,769 (10,383)
匯兌對現金、現金等價物和受限制的現金的影響10 (33)
現金及現金等價物淨減少額(3,626)(1,757)
期初現金、現金等價物及受限制的現金餘額11,519 9,325 
期末現金、現金等價物及受限制的現金餘額$7,893 $7,568 
附註是這些合併財務報表的一部分。

5

注1報告的基礎和最近發佈的會計準則

合併基礎

施貴寶公司（"bms系統"，"我們"，"我們的"，"我們"或"公司"）根據SEC和美國通用會計準則的要求編制了這些未經審計的合併基本報表，供中期報告使用。根據這些規定，通常需要在年度基本報表中提供的某些腳註和其他財務信息可以進行壓縮或省略。本季度報告在第10-Q表格中包括了公司合併基本報表，其中包括截至2024年9月30日和2023年12月31日的公司財務狀況以及截至2024年9月30日和2023年的三個月和九個月的經營業績和截至2024年9月30日和2023年的現金流量所需的所有調整。所有公司間結算餘額和交易已被取消。這些合併基本報表及相關附註應與公司截至2023年12月31日年度審計合併基本報表一起閱讀，該報表包含在2023年第10-k表格中。請參考本季度10-Q表格末尾的縮略語總覽，以了解全文中使用的術語。

業務部門信息

bms系統在一個領域運營，從事發現、開發、許可、製造、營銷、分銷和銷售幫助患者戰勝嚴重疾病的創新藥物。一家全球研發組織和供應鏈組織負責產品的發現、開發、製造和供應。區域型商業機構營銷、分銷和銷售產品。該業務還得到全球公司職能部門的支持。與BMS的運營結構一致，作爲首席運營決策者的首席執行官（"CEO"）在全球公司層面管理和分配資源。在全球公司層面管理和分配資源使CEO能夠評估可用資源的總體水平，以及如何根據我們長期的公司範圍戰略目標最佳地在各個職能、治療領域、區域型商業機構和研發項目之間分配這些資源，而不是以產品或特許經營爲基礎。單一部門的確定與CEO定期審查的財務信息一致，目的是評估績效、分配資源、制定激勵補償目標，以及規劃和預測未來時期。有關產品和區域型營業收入的更多信息，請參閱"—注2. 營業收入"。

估計和判斷的使用

收入、支出、資產和負債在每個季度可能會有所變化。因此，這些未經審計的合併財務報表中的結果和趨勢可能不代表全年營業成果。編制財務報表需要使用管理層的估計、判斷和假設。其中最重要的假設是用於確定收購會計、無形資產減值、退款、現金折扣、銷售折扣、退貨和其他調整、法律事項準備和所得稅的估計。實際結果可能與估計值有所不同。

尚未採用最近發佈的會計標準

所得稅

2023年12月，FASB發佈了關於所得稅披露的修訂指引。該指引旨在爲有效所得稅率協調和所得稅支付披露提供額外的細分。修訂後的指引適用於2025年1月1日起的年度，並應採用前瞻性基礎。允許提前採納。

《修訂和重新制定的2020年The Aaron's Company, Inc.股權和激勵計劃》，（參考到2024年5月16日提交給美國證券交易委員會的S-8表格附註4.3）。

2023年11月份，FASB發佈了修訂後的指導意見，用於改進可報告部門披露。修訂後的指導意見要求公衆實體定期披露由首席經營決策者（CODM）定期審查的重要部門費用，包括只有一個可報告部門的公衆實體。修訂後的指導意見適用於從2024年1月1日開始的財政年度和從2025年1月1日開始的中期期間，並應以溯源方式應用。允許提前採納。

6

註釋2。營業收入

以下表格總結了按性質分解的營業收入：
截至9月30日的三個月截至9月30日的九個月
以百萬美元計2024202320242023
產品淨銷售額$11,483 $10,645 $34,967 $32,610 
聯盟收入105 138 355 461 
其他收入
304 183 636 458 
總收入$11,892 $10,966 $35,958 $33,529 

以下表格總結了GTN調整:
截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
總銷售產品額$21,223 $18,648 $61,298 $54,047 
GTN調整(a)
退款和現金折扣(2,967)(2,373)(8,366)(6,743)
醫療補助和醫療保險回扣(4,577)(3,730)(11,525)(9,355)
其他回扣、退款、折扣和調整(2,196)(1,900)(6,440)(5,339)
GTN調整總計(b)
(9,740)(8,003)(26,331)(21,437)
產品淨銷售額$11,483 $10,645 $34,967 $32,610 
(a) 包括對GTN調整的減少，用於商品銷售，這些銷售發生在先前期間，原因是估計變更爲 $421百萬美元和103XXX萬181百萬美元和116截至2023年9月30日，分別爲三個月和九個月的總營收爲百萬美元。
(b) 包括2024年9月30日和2023年9月30日結束的三個和九個月的美國GTN調整，分別爲$billion和$billion。8.9億美元和23.9億爲2024年9月30日結束的三個和九個月，$billion，分別爲2023年9月30日結束的三個和九個月的億。7.3私人股權和其他投資的金額分別爲52.27億美元和53.98億美元，截至2023年7月31日和2023年1月31日。19.2 億爲2024年9月30日結束的三個和九個月，$billion，分別爲2023年9月30日結束的三個和九個月的億。

7

下表總結了按產品和地域板塊劃分的營業收入。
截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
增長投資組合
Opdivo$2,360 $2,275 $6,825 $6,622 
奧倫西亞936 925 2,682 2,616 
Yervoy642 579 1,855 1,672 
瑞必澤447 248 1,226 688 
歐普杜阿格233 166 674 437 
Abecma124 93 301 372 
澤波西亞147 123 408 301 
Breyanzi224 92 484 263 
Camzyos156 68 379 143 
Sotyktu66 66 163 107 
Augtyro10 — 23 — 
Krazati34 — 87 — 
其他增長產品(a)
433 311 1,093 886 
總增長投資組合
5,812 4,946 16,200 14,107 
傳統投資組合
Eliquis3,002 2,705 10,138 9,332 
Revlimid1,412 1,429 4,434 4,647 
Pomalyst/Imnovid898 872 2,722 2,551 
Sprycel290 517 1,088 1,404 
Abraxane253 260 701 757 
其他傳統產品(b)
225 237 675 731 
全部傳統產品組合
6,080 6,020 19,758 19,422 
總營收$11,892 $10,966 $35,958 $33,529 
美國$8,232 $7,542 $25,509 $23,298 
國際3,389 3,239 9,803 9,716 
其他(c)
271 185 646 515 
總營收$11,892 $10,966 $35,958 $33,529 
（a）包括 Onureg, Inrebic, Nulojix, Empliciti 和版稅收入。
(b) 包括其他成熟品牌。
(c) 其他收入包括聯盟相關收入，這些產品不是由bms系統的區域型商業組織銷售。

自2024年開始，波多黎各的收入納入國際收入。之前的金額已經重新分類以符合當前的呈現方式。

營業收入來自在之前期間滿足的履約義務，金額爲$238萬美元和496 百萬。1141百萬美元和355分別爲2023年9月30日結束的三個月和九個月，主要包括外部授權安排的版稅和與之前銷售相關的GTN調整的修正估計。

注3. 聯盟

bms系統與第三方達成合作安排，共同開發和商業化某些產品。儘管這些安排各自獨特，但雙方均是合作運營活動的積極參與者，並根據活動的商業成功承擔重要風險和回報。bms系統將這些合作稱爲聯盟，將合作伙伴稱爲聯盟夥伴。

8

有關聯盟的選定財務信息如下，包括當bms系統是第三方客戶銷售產品聯盟產品的主要時的淨產品銷售額。以下總結的費用不包括與聯盟產品活動相關的所有金額，而只包括聯盟夥伴之間的付款或相關攤銷，如果付款被推遲或資本化。

截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
聯盟收入
產品淨銷售額$3,091 $2,762 $10,323 $9,614 
聯盟收入105 138 355 461 
總聯盟收入$3,196 $2,900 $10,678 $10,075 
與聯盟夥伴之間的款項（來自/去向）
銷售產品成本$1,496 $1,330 $5,013 $4,650 
營銷、銷售和行政(76)(52)(220)(190)
研發50 1 150 81 
Acquired IPRD — — 880 55 
其他收入/費用，淨額(12)(10)(126)(37)

美元數百萬9月30日,
2024		2023年12月31日,
2023
選定的聯盟資產負債表信息
應收款 - 來自聯盟合作伙伴$190 $233 
應付款 - 支付給聯盟合作伙伴1,455 1,394 
遞延收入 - 來自聯盟(a)
236 274 
(a) 包括未攤銷的預付款和節點支付。

關於公司重要聯盟的性質、目的、重要權利和義務以及特定的會計政策選擇，在2023年的Form 10-k中有討論。截至2024年9月30日和2023年結束的九個月內，有關聯盟的重大發展和更新如下所述。

SystImmune

bms系統與SystImmune, Inc.（以下簡稱"SystImmune"）是全球戰略合作伙伴，共同開發和商業化BL-B01D1，這是一種基於雙特異性拓撲異構酶抑制劑的抗體藥物偶聯物，目前正在進行鍼對轉移性或不可切除的非小細胞肺癌的I期臨床試驗，同時也在針對乳腺癌和其他腫瘤類型進行開發。bms系統支付了前期費用$800百萬，這已在截至2024年9月30日的九個月內計入收購的知識產權和研發資產。bms系統還承擔在實現有條件的開發、監管和基於銷售的里程碑後支付高達$7.6十億的義務。

各方將共同開發並商業化BL-B01D1，在美國分享利潤和虧損。SystImmune將負責在中國大陸的開發、商業化和bms系統，並負責製造某些用於中國大陸以外的藥物供應，BMS將根據淨銷售額獲得版稅。BMS將負責在全球其他地區的開發和商業化，SystImmune將在淨銷售額中獲得版稅。

Eisai

2024年6月，BMS和Eisai同意結束全球戰略合作，共同開發和商業化MORAb-202，原因是BMS內部持續進行的投資組合優先事項。所有MORAb-202的權利和義務都轉讓給了Eisai，而BMS將收到$90 百萬作爲終止的一部分，這筆款項包含在2024年9月30日結束的九個月之內的其他（收入）/費用中，其中有$85 百萬在2024年第三季度期間收到。

9

注意事項4：供應鏈融資計劃收購、剝離、許可及其他安排

資產 收購

卡魯納

2024年3月18日，BMS收購了Karuna，這是一家處於臨床階段的生物製藥公司，致力於發現、開發和提供改變人們與精神和神經狀況生活的革命性藥物。這次收購爲BMS提供了權利 Cobenfy （xanomeline和trospium chloride），前稱KarXt。 Cobenfy 是一種具有新穎作用機制和不同效力和安全性的抗精神病藥物，於2024年9月26日獲得FDA批准，用於成年人精神分裂症的治療。 Cobenfy 也在針對精神分裂症中現有標準治療藥物的輔助療法以及治療阿爾茨海默病患者的精神症狀的註冊試驗中。

BMS以美元的價格收購了Karuna普通股的所有已發行和流通股330.00 全現金交易中的每股，總對價爲美元14.0十億美元，或美元12.9淨收購現金淨額爲十億美元。此次收購的資金主要來自債務收益（見 「——註釋10。融資安排」（詳情請見）。此後，該交易被視爲資產收購 Cobenfy 幾乎佔所購總資產的公允價值。結果，$12.1在截至2024年9月30日的九個月中，收購的IPRD花費了10億美元。

以下總結了轉移的總對價及其在收購資產、承擔的負債和收購的知識產權開發費用中的分配：

美元數百萬
未結算股份的現金支付 $12,606 
股權獎勵的現金支付 1,421 
待支付的考慮因素14,027 
減：未歸屬股權獎勵的費用(a)
(289)
交易成本55 
分配的總考慮因素$13,793 
現金及現金等價物$1,167 
其他資產67 
無形資產100 
遞延所得稅資產 542 
遞延所得稅負債(25)
其他負債(180)
已獲取可識別資產淨額
1,671 
已獲得的研發費用支出12,122 
分配的總對價
$13,793 
（a）包括截至2024年9月30日的九個月期間在市場營銷和行政支出的$百萬和在研發支出的$百萬的現金結算的未獲配股權獎勵。130百萬在市場營銷、銷售和行政支出以及$百萬在截至2024年9月30日的九個月期間的研究與開發方面支出中支出。159百萬在截至2024年9月30日的九個月期間的研究與開發開支中支出。

商業組合

RayzeBio

在2024年2月26日，bms系統收購了RayzeBio，這是一家臨床階段的放射藥物療法（"RPT"）公司，專注於基於錒的RPT用於實體瘤。此次收購爲bms系統提供了RayzeBio的基於錒的放射藥物平台及其主要資產RYZ101，該資產目前正在進行III期開發，用於治療胃腸胰神經內分泌腫瘤。

bms系統收購了RayzeBio所有已發行和流通的普通股，交易金額爲$62.50 的現金交易，總對價爲$4.1十億，或$3.6 億，扣除收購現金。此次收購由手頭現金和債務收益組合資金支持（詳見"—附註10. 融資安排"）。

該交易被視爲一種業務合併，要求所有板塊資產和負債在收購日期按公允價值確認。

收購的總代價包括以下內容：
10

美元數百萬
針對未發行股份的現金對價 $3,851 
針對股權獎勵的現金對價 296 
已支付的對價4,147 
減：未歸屬股票獎勵(a)
(274)
總分配對價$3,873 
(a) 包括在2024年9月30日結束的九個月期間支出的用於未歸屬股權獎勵的現金結算金額$159百萬，支出在營銷、銷售和管理方面以及在研發方面。115百萬，支出在2024年9月30日結束的九個月期間研發。

購買價格分配導致根據其各自的公允價值總結如下的資產和負債在收購日被分配到。
美元數百萬
購買價格分配
現金及現金等價物$501 
其他資產70 
無形資產 3,700 
遞延所得稅資產81 
遞延所得稅負債(798)
其他負債(109)
可識別的淨資產收購$3,445 
商譽 428 
分配的總對價$3,873 

無形資產包括 $1.7 十億的無限使用期的知識產權開發項目和 $2.0 十億的研發科技。無限使用期的知識產權開發項目和研發科技的估計公允價值是採用收益法評估確定的。商譽主要是由於確認遞延稅負債而產生，稅務上不可抵扣。

Mirati

2024年1月23日，bms系統收購了Mirati，一家處於商業階段的靶向抗癌公司，獲得了肺癌藥物Krazati的商業化權利， Krazati， 以及包括PRMT5抑制劑（前稱MRTX1719）在內的多個臨床資產， Krazati 它是一種經FDA批准的KRAS突變抑制劑，作爲NSCLC患者的二線治療，G12C 並正在與PD-1抑制劑聯合開發，作爲NSCLC患者的一線治療。 Krazati 還在臨床開發中，作爲單一藥物以及組合治療，用於其他適應症。PRMT5抑制劑是一種潛在的首個MTA合作式PRMT5抑制劑，目前處於I期開發中。bms系統獲得了若干其他臨床和臨床前階段的資產，包括額外的KRAS抑制劑和支持性項目。

bms系統收購了Mirati發行的所有流通普通股，每股價格爲$58.00 的現金交易，總對價爲$4.8十億，或$4.1十億，扣除收購的現金。Mirati的股東還收到了每持有一股Mirati普通股即獲得的 一份 不可交易的或有價值權利(CVR)，每股可能價值$12.00 每股以現金方式支付$，總價值約爲$。1.0十億。該有價值權利的支付受到FDA接受針對特定適應症的PRMT5抑制劑的新藥申請(NDA)的限制。 七年 交易結束的部分。此次收購的資金來源於手頭現金和債務收益的結合（詳見「—注10。融資安排」）。

該交易被視爲一種業務合併，要求所有板塊資產和負債在收購日期按公允價值確認。

11

收購的總代價包括以下內容：
美元數百萬
未結算股份的現金支付 $4,596 
股權獎勵的現金支付 205 
已支付的對價4,801 
加上：認股權證的公允價值248 
減去：未獲授予的股票獎勵(a)
(114)
分配的總考慮因素$4,935 
(a) 包括截至2024年9月30日止九個月在研發費用中支出的未獲授予權益獎勵的現金結算$60百萬，支出在營銷、銷售和管理方面以及在研發方面。54百萬。

購買價格分配導致根據其各自的公允價值總結如下的資產和負債在收購日被分配到。
美元數百萬
購買價格分配
現金及現金等價物$748 
存貨215 
其他資產159 
無形資產4,225 
734 
遞延所得稅負債(1,094)
其他負債(204)
可識別的淨資產收購$4,783 
商譽152 
分配的總考慮因素$4,935 

庫存包括美元的公允價值調整148百萬。無形資產包括 $640 數百萬份有期限的已購上市產品版權（克拉扎蒂) 和 $3.5數十億無限期的IPRD資產。固定期限的收購上市產品權利和無限期的IPRD資產的估計公允價值是使用收益法估值方法確定的。 商譽主要來自遞延所得稅負債的確認，不能用於稅收目的的扣除。

Karuna、RayzeBio和Mirati的經營業績和現金流量結果從各自收購日期起納入合併基本報表，且未達到重要性。受收購實體的歷史財務業績不顯著。

出售

以下表格總結了剝離項目的財務影響，包括包含在其他收入/費用中的版稅。所有剝離項目的營業收入和稅前收益在所有報告期內均不重要（不包括剝離項目的收益或損失）。
截至9月30日的三個月
淨募資剝離（收益）/損失特許權收入
美元數百萬202420232024202320242023
糖尿病業務 - 版權費
$278 $220 $— $— $(284)$(217)
成熟產品和其他3 3 5 — — — 
總計$281 $223 $5 $— $(284)$(217)
截至9月30日的九個月
淨募資剝離（收益）/損失特許權收入
美元數百萬202420232024202320242023
糖尿病業務 - 許可費
$774 $621 $— $— $(820)$(623)
成熟產品和其他3 10 5 — — — 
總計$777 $631 $5 $— $(820)$(623)

12

許可和其他安排

下表總結了金融影響。 Keytruda* 特許權使用費， Tecentriq* 特許權使用費，預付款許可費和未獲得商業批准的產品里程碑，這些都包含在其他（收入）/支出淨額中。

截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
是Merck Sharp and Dohme LLC的註冊商標，其爲Merck & Co.，Inc.的子公司，總部位於美國新澤西州羅唆市,USA。* 特許權使用費
$(137)$(315)$(407)$(878)
Tecentriq* 特許權使用費
(12)(24)(35)(78)
有條件里程碑收入(13)— (38)(36)
遞延收入攤銷(12)(12)(36)(39)
其他版稅和許可收入 (6)(14)(16)(37)
版稅和許可收入$(180)$(365)$(532)$(1,068)

Keytruda*專利許可協議

bms系統和Ono是與默沙東關於默沙東的PD-1抗體相關的全球專利許可協議的各方 是Merck Sharp and Dohme LLC的註冊商標，其爲Merck & Co.，Inc.的子公司，總部位於美國新澤西州羅唆市,USA。*. 根據協議，默沙東支付全球銷售的持續版稅 是Merck Sharp and Dohme LLC的註冊商標，其爲Merck & Co.，Inc.的子公司，總部位於美國新澤西州羅唆市,USA。* 的 6.5％直至2023年12月31日，並有責任支付從2024年1月1日至2026年12月31日的％。公司還就各自涉及PD-1的專利組合授予彼此一定的權利。在調整各方的法律費用後，支付和版稅在bms系統和Ono之間按照 2.5的百分比分配，分別是 75/25 在每方的法律費用調整後，在bms系統和Ono之間以相應的百分比分配支付和版稅。

注5. 其他（收入）/費用，淨額
截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
利息費用（備註10）$505 $280 $1,451 $850 
特許權和許可收入（備註4）(180)(365)(532)(1,068)
特許權收入 - 剝離（備註4）
(284)(217)(820)(623)
投資收益(94)(107)(364)(304)
訴訟及其他和解 (a)
— (61)71 (393)
重組準備金（註釋6）78 141 558 321 
整合費用（註釋6）69 54 214 180 
股權投資（收益）/損失（註釋9）
(12)— (221)213 
收購費用（註釋4）
— — 50 — 
無形資產減值
47 29 47 29 
其他(b)
105 (12)134 8 
其他收入/費用，淨額
$234 $(258)$588 $(787)
(a) 包括截至2024年9月30日的Eisai合作終止所產生的收入$90百萬和截至2023年9月30日的Nimbus TYK2計劃變更控制條款所產生的收入$400百萬。
(b)    包括$的養老金結算費用100在截至2024年9月30日的三個月內爲百萬119在截至2024年9月30日的九個月內爲百萬，這與施貴寶波多黎各公司的養老收入養老金計劃的終止有關。

訴訟和其他和解

百濟神州和解

在2023年8月，bms系統與百濟神州（"百濟神州"）達成了一項協議，終止了雙方的所有合同關係，並解決了所有正在進行的爭議和索賠，包括與許可證和供應協議及相關仲裁程序有關的爭議，這些內容之前已經披露。 Abraxane 根據該協議，bms系統同意將按股權認購協議持有的百濟神州普通股中轉讓的權益爲 23.3 百萬股，導致在截至2023年9月30日的三個月和九個月中，計入其他（收入）/支出淨額的費用爲$322百萬。該費用是根據轉讓當天股票的收盤價確定的。
13


阿斯利康結算

在2023年7月，bms系統與阿斯利康達成協議，以解決兩方在CTLA-4訴訟中所有未決索賠，以及 二 PD-L1抗體訴訟。阿斯利康將向bms系統支付總計$560百萬美元，作爲 四 到2026年9月的支付，這將與小野藥品和達納-法伯共享。bms系統的分享約爲$418百萬，其中淨現值$384 百萬反映在截至2023年9月30日的三個月和九個月內的其他（收入）/費用中。

註釋6。重組

2023年重組計劃

2023年，BMS啓動了一項重組計劃，通過發展和簡化其在研發、製造、商業和其他職能等關鍵領域的企業運營模式，加快向患者交付藥物，以確保其運營模式支持並與公司投資關鍵優先事項的戰略保持適當一致。這些變化主要包括（i）轉變研發業務以加快管道交付，（ii）增強我們的商業運營模式，以及（iii）建立響應速度更快的製造網絡和擴大我們的細胞療法制造能力。根據我們在今年早些時候公佈的優先順序和效率目標，BMS繼續通過投資組合優先順序和運營成本管理來執行戰略生產力計劃。根據2023年重組計劃，到2026年將產生的預期重組成本總額約爲美元1.5十億。這些成本主要包括員工解僱費用，在較小程度上包括場地退出成本，包括不動產、廠房和設備的減值和加速折舊。

賽諾菲和其他收購計劃

啓動了重新結構和整合計劃，以實現由於對Celgene（2019）、Turning Point（2022）、Mirati（2024）、RayzeBio（2024）和Karuna（2024）的收購帶來的預期成本協同效應而產生的成本節省和避免。針對這些計劃，剩餘的費用約爲$350 百萬美元，主要包括員工解僱成本、IT系統整合成本，以及在較小程度上的場站退出成本，包括產業資產的減值和加速折舊。

14

以下內容提供了與重組舉措相關的費用，按成本類型分類：
截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
2023年重組計劃$180 $149 $512 $380 
賽諾菲和其他收購計劃83 131 420 269 
總費用$263 $280 $932 $649 
員工解僱費用$77 $135 $554 $309 
其他終止成本1 6 4 12 
重組準備78 141 558 321 
整合費用69 54 214 180 
加速折舊22 15 56 28 
DEC(a)
93 70 95 120 
其他關機成本
1 — 9 — 
總費用$263 $280 $932 $649 
產品銷售成本$88 $16 $105 $53 
營銷、銷售和行政7 65 19 85 
研發21 4 36 10 
其他收入/費用，淨額147 195 772 501 
總費用$263 $280 $932 $649 
(a)    其中包括價值爲 87在截至2024年9月30日的三個月內，因網站減值而產生的百萬美元，以及$65在截至2023年9月30日的三個月內，因設施租賃而產生的百萬美元減值費用。

以下總結了與重組計劃活動相關的費用和支出：
截至9月30日的九個月
美元數百萬20242023
期初餘額$188 $47 
重組準備558 321 
外幣翻譯及其他— (3)
支付(432)(142)
結束餘額$314 $223 

注7。所得稅
截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
稅前收益/(虧損)
$1,676 $2,137 $(8,554)$6,766 
所得稅費用
461 203 455 488 
有效稅率27.5 %9.5 %(5.3)%7.2 %

中期期間所得稅準備根據預計年度有效稅率和立即反映的零星項目的稅收影響確定。截至2024年9月30日的三個月的有效稅率主要受到以往估計的年度有效稅率的變化對司法收入組合的影響。

2024年9月30日結束的九個月的有效稅率受到10億美元一次性、不可抵稅的收購Karuna費用的影響12.1以及與Celgene 2017-2019年度IRS審計解決以及收購無形資產攤銷所導致的司法收入的混合有關的1億美元的所得稅準備金釋放。644以及與Celgene 2017-2019年度IRS審計解決以及收購無形資產攤銷所導致的司法收入的混合有關的1億美元的所得稅準備金釋放。

截至2023年9月30日的三個月內，實際稅率主要受到第174條關於某些非美國研究和開發費用可扣除性的指導的影響。修訂後的指導導致2022年之前估計的所得稅減少，這在2023年第三季度得以體現，同時也減少了對2023年預計的年度有效稅率。2022年之前估計的所得稅大約減少了$240百萬美元，主要是因爲在2023年第三季度發佈的上述修訂的第174條指導，這在美國聯邦稅務申報的最終確定時得以確認。

15

除了上述第174條指導意見的影響外，截至2023年9月30日的九個月期間，實際稅率受到一個$656 百萬的遞延所得稅收益的影響，此收益是在收到有關子公司投資法定減值的可扣除性的非美國稅務裁定後產生的，以及由於收購的無形資產的攤銷、股權投資損失、訴訟和其他和解，以及$89 百萬與解決Celgene在2009-2011年期間的IRS審計相關的所得稅準備金釋放。

由於各種原因，包括預計稅前收益組合和稅務準備金的變化，以及修訂的解釋或變更稅法法規，未來期間可能會出現對有效稅率的額外變化。

截至2024年和2023年9月30日的九個月期間，所得稅支付爲$3.1億和美元4.12024年4月1日，我們以,十億美元脫售我們在聯盟管道中的股權,%的Aux Sable投資（包括%，與Aux Sable Midstream LLC和Aux Sable Liquid Products有限合夥企業的權益）以及我們在NRGreen Power有限合夥企業中的權益的股權，部分買家是Pembina Pipeline Corporation，合同總價爲億美元，已計算億美元的不可追溯債務，尚需遵循正常的結算條件。在2024年6月30日結束的三個和六個月的合併損益表中，資產出售所實現的損益爲稅前,十億美元，抵扣了攜帶的,十億美元商譽，所以損益總額爲,十億美元。我們在聯盟管道和Aux Sable的權益投資先前包含在我們的燃料幣傳輸板塊中，而我們在NRGreen的權益投資先前包含在我們的可再生電力板塊中。799百萬美元和$567分別爲千萬元，用於遵循TCJA實施的過渡稅。

bms系統目前正接受多個稅務機構的審查，這些機構提出或正在考慮就諸如轉讓定價、某些稅收抵免和某些費用的可扣稅金額等問題提出實質性調整。如先前披露的，bms系統接到了若干與轉讓定價和其他稅務問題有關的2008年至2012年稅收年度的IRS擬議調整通知。bms系統對IRS的立場持有異議，並繼續與IRS合作解決這些問題。2022年第四季度，bms系統已進入IRS行政上訴程序，以解決這些問題。這些複雜事項的最終解決時間尚不確定，可能對bms系統的合併基本報表產生實質影響。

有理由相信，截至2024年9月30日，未確認稅務福利的金額可能在未來12個月內下降約$區間907百萬130 由於解決某些稅務稽覈和其他事件，預計未確認稅務福利的變化可能導致支付額外稅款、調整某些遞延稅款和/或確認稅務福利。

稅務機關可能會提出新的問題，這可能會增加未確認的稅收利益，但目前無法合理地估計這種增加。bms系統相信它已對所有開放的稅務年度進行了充分的準備。

註釋8.每股收益/(虧損)
截至9月30日的三個月截至9月30日的九個月
以百萬美元爲單位，除每股數據外2024202320242023
歸屬bms系統的淨收益/(損失)
$1,211 $1,928 $(9,020)$6,263 
基本加權平均流通股數2,028 2,057 2,026 2,083 
歸因於股權激勵計劃的增量股份3 7 — 10 
攤薄加權平均流通股數2,031 2,064 2,026 2,093 
普通股每股收益/(損失)
基本$0.60 $0.94 $(4.45)$3.01 
攤薄0.60 0.93 (4.45)2.99 

因爲反稀釋影響而被排除在稀釋（虧損）/普通股每股收益計算之外的潛在普通股總數是 25百萬和 41百萬美元，分別爲截至2024年9月30日的三個和九個月，在綜合損益簡表上。 在測試商譽減值時，公司可以選擇 對於截至2023年9月30日的三個月和九個月來說，這是重要的。

16

注9。金融工具和公允價值計量

定期以公允價值計量的金融資產和負債總結如下：
2024年9月30日2023年12月31日
美元數百萬第1級二級第3級第1級二級第3級
現金及現金等價物
貨幣市場和其他證券$— $5,589 $— $— $8,489 $— 
有價證券
定期存款— 18 — — 609 — 
商業本票— — — — 92 — 
企業債務證券— 483 — — 460 — 
美國財政證券— 27 — — 19 — 
衍生資產— 271 — — 219 — 
股權投資600 88 — 318 141 — 
衍生負債— 173 — — 160 — 
待定對價負債
有價證券授權(a)
2 — 248 4 — — 
其他收購相關的待定對價— — — — — 8 
(a) 包括與Mirati收購相關的待定價值權益的公允價值，詳見"-附註4.收購、剝離、許可和其他安排"。待定價值權益的公允價值是使用概率加權的預期回報方法估計的。

根據公司2023年10-k表格中"項目8.基本報表和附加數據—注9.金融工具和公允價值計量"進一步描述，公司公平價值估計採用以下輸入: 要麼是(1)在活躍市場中的相同資產或負債的報價價格（1級輸入）; 要麼是(2)在活躍市場中相似資產或負債的觀察價格或者在不活躍市場中的相同或相似資產或負債的價格（2級輸入）; 要麼是(3)不可觀察的輸入（3級輸入）。2級權益投資的公平價值會根據特定於安防-半導體的特徵進行調整，而不會根據合同銷售限制進行調整。截至2024年9月30日和2023年12月31日，受合同銷售限制的權益投資不構成重大數額。

可交易債務證券

可交易債務證券的攤銷成本接近其公允價值，並且這些證券將在 五年 截至2024年9月30日到期，且 四年包銷商在擬議公開發行結束時獲得了25,875股A類普通股。向包銷商發行的股票公允價值爲$。

下面討論了我們的市場股票、非市場股票、市場和非市場股票的收益和損失，以及我們按權益法計量的股票。

以下是股權投資的賬面價值彙總：
美元數百萬9月30日,
2024		2023年12月31日,
2023
帶有RDFV的股權投資
$688 $459 
不帶RDFV的股權投資
841 698 
有限合夥企業及其他股權法投資578 542 
所有權益投資$2,107 $1,699 

17

以下總結了與股權投資相關的活動。股權投資公允價值變動計入其他（收入）/費用，淨額。
截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
具有RDFV的股權投資
已確認的淨利潤/損失
$(33)$15 $(155)$203 
已出售投資產生的淨利潤/損失減少
(3)(86)(2)2 
仍持有的投資產生的淨未實現利潤/損失
(30)101 (153)201 
沒有RDFV的股權投資
期末總賬面價值上調
(15)(3)(36)(9)
出售投資所確認的淨實現利潤（損失）
— — (36)— 
減值和下調
13 6 42 6 
有限合夥企業和其他權益法投資
對聯營公司淨損失（收入）的權益
23 (18)(36)13 
總共的股權投資（收益）/損失
$(12)$— $(221)$213 

截至2024年9月30日，基於可觀察價格變化的累計上調、累計減值和下調在未按公允價值計量的股權投資中仍爲$220百萬美元和$98百萬。

合格對沖和不合格衍生品

現金流套期保值

BMS簽訂外幣遠期和購買的當地貨幣看跌期權合約（外匯合約），以對沖某些預測的公司間庫存銷售、第三方銷售和某些其他外幣交易。這些外匯合約的目標是減少外匯匯率變動造成的波動性，這種變化將影響來自外幣計價銷售（主要是歐元和日元）的未來現金流的美元價值。這些衍生品合約的公允價值在合併資產負債表中記錄爲資產（收益頭寸）或負債（虧損頭寸）。這些被指定爲現金流套期保值的外匯合約的公允價值變動暫時記錄在累計其他綜合虧損（「AOCL」）中，並在套期保值項目影響收益時（通常在未來24個月內）重新歸類爲淨收益。假設市場利率在合同到期前保持不變，截至2024年9月30日，BMS預計將稅前虧損重新歸類爲美元23在接下來的12個月中，我們的外匯合約從AOCL出售的產品成本爲百萬美元。未償還的外幣兌換合約的名義金額主要爲美元4.1歐元合約爲十億美元，美元1.2截至2024年9月30日，日元合約爲十億美元。

18

bms系統還通過跨貨幣掉期合同來對沖與其以歐元計價的長期債務相關的外匯匯率風險。這些合同將長期債務的利息支付和本金償還從歐元轉換爲美元，並被指定爲現金流對沖。對此類合同的未實現的收益和損失在其他綜合收益中報告，並在被對沖的債務影響收益的相同期間重新分類爲其他（收入）/支出，淨額。與以歐元計價的長期債務相關的跨貨幣掉期合同的名義金額爲$1.2 十億，截至2024年9月30日。

2024年1月，bms系統進入了總名義價值爲$的遠期利率合約，用於對沖與2024年2月發行的無擔保優先票據相關的未來利率風險。5.0美元的遠期利率合約被指定爲現金流量對沖，並在無擔保優先票據發行後終止。這筆交易的$百萬收益已計入其他綜合（損益）並按相關債務期限逐步減記利息費用。在隨後的12個月內預計對遠期利率合約進行確認的金額不重要。1312024年1月，bms系統進入了總名義價值爲$的遠期利率合約，用於對沖與2024年2月發行的無擔保優先票據相關的未來利率風險。

現金流對沖會計在預計交易在最初預計日期後的60天內不再可能發生或對沖不再有效時終止。判斷指定爲合格對沖的衍生工具在抵消被對沖項目現金流變化方面是否高度有效的評估在開始時和每季度進行一次。在所有報告期間，與已終止現金流對沖和對沖無效性相關的收益影響不重大。未指定爲現金流對沖的外匯兌換合同對某些以外幣計價的資產、負債和收益的風險進行對沖。這些衍生工具公允價值的變化在發生時計入收益。

淨投資套期保值

跨幣種掉期合約和美元的外幣遠期合約1.5截至2024年9月30日，有10億美元被指定用於對沖BMS對其外國子公司的淨投資的貨幣敞口。合約公允價值變動記錄在AOCL的外幣折算部分中，並在合併資產負債表中相應抵消衍生資產或負債。未償還的跨貨幣互換和外幣遠期合約的名義金額主要歸因於日元的美元713百萬歐元和美元721截至 2024 年 9 月 30 日，百萬人。

2023年，公司取消了其剩餘的歐元負債淨投資對沖。375百萬。相關的淨投資對沖是爲了對沖在某些外國子公司的淨投資中的歐元貨幣風險，並被確認爲長期債務。在重新計量以歐元計價的債務上，匯率變動的有效部分包括在其它綜合收益的匯兌差額中，相應的抵消在長期債務中。

截至2024年9月30日的三個月和九個月期間，與我們淨投資對沖中不被包含在有效性評估中的部分相關的收益的攤銷不重大。

公允價值套期保值

固定收益與浮動利率互換合同被指定爲公允價值套期保值，並用作利率風險管理策略來創造固定和浮動利率債務的適當平衡。套期保值基準風險的合同和基礎債務按公允價值記錄. 由於基礎債務公允價值變動產生的收益或損失歸因於套期基準利率風險，在利息費用中記錄，同時關聯抵銷債務賬面價值。由於互換的具體條款和名義金額旨在與進行套期的債務保持一致，互換的公允價值變動將在利息費用中記錄，並關聯抵消合併資產負債表中的衍生資產或負債。因此，收益沒有淨影響。如果基礎互換在到期前終止，則基礎債務的公允價值調整將作爲剩餘債務期限內的利息費用減少。

衍生現金流（淨投資對沖除外）主要在合併現金流量表的經營項目中分類，與基礎對沖項目一致。與淨投資對沖相關的現金流被歸類爲投資活動。

19

下表總結了未到期衍生品的公允價值和名義價值：
 2024年9月30日
2023年12月31日
資產(a)
負債(b)
資產(a)
負債(b)
美元數百萬名義公允價值名義公允價值名義公允價值名義公允價值
指定爲現金流量套期交易
外匯兌換合約
$5,246 $110 $1,193 $(41)$4,772 $130 $1,971 $(66)
貨幣互換合約1,210 53 — — 1,210 50 — — 
指定爲淨投資套期保值
外匯兌換合約
378 5 448 (7)— — 215 (8)
貨幣互換合約308 3 400 (29)— — 747 (43)
指定爲公允價值對沖工具
利率掉期合同3,500 19 255 (8)2,500 3 1,755 (14)
未指定爲對沖工具
外匯兌換合約4,468 76 5,180 (88)906 20 1,250 (29)
總回報掉期合約 (c)
$455 $5 $— $— $401 $16 $— $— 
（a）包括在其他流動資產和其他非流動資產中。
(b)    包括在其他流動負債和其他非流動負債中。
(c)    總回報掉期合同對某些遞延補償負債的公允價值變化進行對沖。

下表總結了金融報表的分類以及在對沖中確認的（收益）/損失金額：
截至2024年9月30日的三個月截至2024年9月30日的九個月
美元數百萬產品銷售成本其他收入/費用，淨額產品銷售成本其他收入/費用，淨額
外匯兌換合約$(3)$7 $(77)$(46)
貨幣互換合約— (55)— (19)
利率掉期合同— 4 — 11 
遠期利率合約
— (1)— (3)
截至2023年9月30日的三個月截至2023年9月30日的九個月
美元數百萬產品銷售成本其他收入/費用，淨額產品銷售成本其他收入/費用，淨額
外匯兌換合約$(51)$(40)$(261)$(100)
貨幣互換合約— 26 — (2)
利率掉期合同— — — (7)
20

下表總結了指定爲對沖的衍生工具和非衍生工具在其他綜合收益中的影響：
截至9月30日的三個月截至9月30日的九個月
美元數百萬2024202320242023
被指定爲現金流量套期保值工具的衍生品
匯率期貨合同收益/(損失)：
在其他綜合收益/(損失)中確認
$(195)$173 $46 $226 
重新分類爲銷售成本(3)(51)(77)(261)
跨貨幣掉期合同收益/(損失)：
確認在其他綜合（損失）/收益中
36 (23)2 5 
重新分類爲其他（收入）/費用，淨額(53)35 (12)26 
遠期利率合約收益/（損失）:
  確認在其他綜合（損失）/收益中
— — 131 — 
重新分類爲其他（收入）/費用，淨額(1)— (3)— 
指定爲淨投資對沖的衍生工具
交叉貨幣掉期合約收益/（損失）:
確認在其他綜合（損失）/收益中
(41)59 9 94
匯率期貨合約收益/(損失):
計入其他綜合收益/(損失)
(75)18 (34)18 
非衍生產品指定爲淨投資對沖
非美元借款收益/(損失):
計入其他綜合收益/(損失)
— — — (10)

注10。融資安排

短期債務義務包括：
美元數百萬9月30日,
2024		2023年12月31日,
2023
非美國短期融資義務
$205 $170 
長期債務的流動部分873 2,873 
其他— 76 
短期債務
$1,078 $3,119 
bms系統可發行最高金額爲$7.0 億美元的無抵押票據，到期日不超過 365 天，從發行日起根據其短期票據計劃。BMS在2024年第一季度發行了$3.0 億美元的短期票據，並於2024年第三季度結束時全額償還。

長期債務和當前部分的長期債務包括：
美元數百萬9月30日,
2024		2023年12月31日,
2023
本金價值$49,025 $38,886 
對本金價值的調整:
利率互換合同的公允價值11 (11)
來自互換終止的未攤銷基礎調整74 82 
未攤銷債券折扣和發行成本(398)(303)
Celgene債券型債務未攤銷購買價格調整835 872 
總計$49,547 $39,526 
長期債務的應付本金$873 $2,873 
長期債務48,674 36,653 
總計$49,547 $39,526 

長期債務的公允價值爲$47.9 億美元，截至2024年9月30日和$36.7 截至2023年12月31日的財務年度，使用基於Level 2的輸入進行估值，這些輸入基於相同或類似債務工具的市場報價。短期債務的公允價值大致等於賬面價值，因爲債務工具的期限較短。
21


在2024年第一季度，bms系統發行了總額爲$13.0十億的無擔保高級票據（"2024年無擔保高級票據"），扣除折扣和貸款發行成本後的收益爲$12.9 十億，具體包括:
本金金額
(以百萬計)
到期於2026年的浮動利率票據(a)
$500 
4.950% 到期於2026年的票據
1,000 
4.900到期日爲2027年的百分比票據
1,000 
4.900% 到期於2029年的票據
1,750 
5.100% 到期於2031年的票據
1,250 
5.200% 到期於2034年的票據
2,500 
5.500% 2044年到期的債券
500 
5.550% 2054年到期的債券
2,750 
5.650% 2064年到期的債券
1,750 
總計$13,000 
(a) 截至2024年9月30日，浮息率等於SOFR＋0.49%.

本公司使用此次發行的淨收益部分用於收購RayzeBio和Karuna（有關更多信息，請參見「—注4. 收購、剝離、許可及其他安排」），其餘淨收益用於一般企業用途。與2024年高級無擔保票據的發行相關，公司終止了$10.0數十億美元 364天 未擔保的延遲提款定期貸款設施，該設施於2024年2月成立，以爲RayzeBio和Karuna的收購提供橋接融資。

2024年9月30日結束的九個月內，$2.5信用協議（「三年信用協議」和五年信用協議合稱「信用協議」）2.900% Notes and $395百萬美元的運營租賃負債的當前部分，分別爲2023年9月30日和2022年12月31日。3.625% 票據已到期並被償還。

截至2023年9月30日的九個月期間，$1.9十億美元債務到期並已償還，包括$750百萬美元的運營租賃負債的當前部分，分別爲2023年9月30日和2022年12月31日。2.750% 註釋，$890百萬美元的運營租賃負債的當前部分，分別爲2023年9月30日和2022年12月31日。3.250% Notes and $239百萬美元的運營租賃負債的當前部分，分別爲2023年9月30日和2022年12月31日。7.150％票據。

利息支付爲$1.4私人股權和其他投資的金額分別爲52.27億美元和53.98億美元，截至2023年7月31日和2023年1月31日。932截至2024年和2023年9月30日的九個月中分別爲 百萬，扣除與利率互換合同相關的金額。

信貸額度

截至2024年9月30日，bms系統擁有一個 五年 $5.0十億的循環信貸設施，計劃於2029年1月到期，可按年度延長 一年 經貸款人同意，另有一個$2.0數十億美元 364天 循環信貸設施計劃於2025年1月到期。這些設施提供了通常的條款和條件，沒有財務契約，並用於爲我們的商業票據借款提供備用流動性。 No 截至2024年9月30日和2023年12月31日，循環保證信貸額度下的借款未償還。

注意事項11。應收賬款
美元數百萬9月30日,
2024		2023年12月31日,
2023
應收賬款$10,092 $9,551 
減少：衝賬和現金折扣(730)(646)
減：預計信用損失準備金(45)(23)
淨貿易應收款項9,317 8,882 
聯盟、特許權使用費、增值稅和其他1,709 2,039 
應收賬款$11,026 $10,921 

非美國應收賬款在無追索權基礎上出售的金額爲$387 百萬美元和美元769 截至2024年9月30日和2023年9月30日的九個月期間，金額爲百萬。應收賬款來自於 三 最大的客戶在美國佔總應收賬款的 72%截至2024年9月30日和2023年12月31日。

22

Note 12. INVENTORIES
Dollars in millionsSeptember 30,
2024		December 31,
2023
Finished goods$1,080 $663 
Work in process3,008 2,430 
Raw and packaging materials343 475 
Total inventories$4,431 $3,568 
Inventories$3,332 $2,662 
Other non-current assets1,099 906 

Note 13. PROPERTY, PLANT AND EQUIPMENT
Dollars in millionsSeptember 30,
2024		December 31,
2023
Land$161 $162 
Buildings6,470 6,495 
Machinery, equipment and fixtures3,741 3,717 
Construction in progress1,367 1,075 
Gross property, plant and equipment11,739 11,449 
Less accumulated depreciation(4,836)(4,803)
Property, plant and equipment$6,903 $6,646 
Depreciation expense was $166 million and $482 million for the three and nine months ended September 30, 2024 and $151 million and $448 million for the three and nine months ended September 30, 2023, respectively.

Note 14. GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

The changes in the carrying amounts in Goodwill were as follows:
Dollars in millions
Balance at December 31, 2023$21,169 
Acquisitions (Note 4)
580 
Currency translation and other adjustments2 
Balance at September 30, 2024
$21,751 

Other Intangible Assets

Other intangible assets consisted of the following:

Estimated
Useful Lives		September 30, 2024December 31, 2023
Dollars in millions
Gross carrying amountsAccumulated amortizationOther intangible assets, net Gross carrying amountsAccumulated amortizationOther intangible assets, net
R&D technology(a)
6 years
$1,980 $(193)$1,787 $— $— $— 
Acquired marketed product rights(a)
3 – 15 years
63,435 (47,048)16,387 63,076 (40,184)22,892 
Capitalized software
3 – 10 years
1,529 (1,114)415 1,497 (1,027)470 
IPRD(a)
8,375 — 8,375 3,710 — 3,710 
Total$75,319 $(48,355)$26,964 $68,283 $(41,211)$27,072 
(a)    Includes assets acquired in connection with Mirati and RayzeBio acquisitions, as further described in "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements."

Amortization expense of Other intangible assets was $2.4 billion and $7.3 billion during the three and nine months ended September 30, 2024 and $2.3 billion and $6.9 billion during the three and nine months ended September 30, 2023, respectively.
23


The other intangible assets impairments were as follows (dollars in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Cost of goods sold
$— $60 $280 (a)$80 
Research and development
— — 590 (b)— 
Other income/(expense)
47 29 47 29 
Total
$47 $89 $917 $109 
(a) Impairment relates to Inrebic, which resulted from lower revised cash flow projections. The charge represented a partial impairment based on the asset's carrying value over its estimated fair value using discounted cash flow projections.
(b) Impairment relates to alnuctamab, which resulted from portfolio prioritization. The charge represented a full write-down of the asset.

Note 15. SUPPLEMENTAL FINANCIAL INFORMATION
Dollars in millionsSeptember 30,
2024		December 31, 2023
Income taxes$3,476 $3,927 
Research and development793 723 
Contract assets393 416 
Restricted cash(a)
2 55 
Other959 786 
Other current assets$5,623 $5,907 

Dollars in millionsSeptember 30,
2024		December 31, 2023
Equity investments (Note 9)$2,107 $1,699 
Operating leases1,348 1,390 
Inventories (Note 12)
1,099 906 
Pension and postretirement225 284 
Research and development363 413 
Restricted cash(a)
1 — 
Receivables and convertible notes
422 436 
Other479 242 
Other non-current assets$6,044 $5,370 
(a)    Cash is restricted when withdrawal or general use is contractually or legally restricted. As of September 30, 2023, restricted cash of $54 million was included in Cash, cash equivalents and restricted cash in the consolidated statement of cash flows.

Dollars in millionsSeptember 30,
2024		December 31, 2023
Rebates and discounts$9,608 $7,680 
Income taxes1,489 1,371 
Employee compensation and benefits1,277 1,291 
Research and development1,300 1,257 
Dividends1,217 1,213 
Interest512 349 
Royalties451 465 
Operating leases165 162 
Other2,072 2,096 
Other current liabilities$18,091 $15,884 

24

Dollars in millionsSeptember 30,
2024		December 31, 2023
Income taxes $1,543 $3,288 
Pension and postretirement447 480 
Operating leases1,483 1,530 
Deferred income247 300 
Deferred compensation477 427 
Contingent value rights (Note 9)
248 — 
Other283 396 
Other non-current liabilities$4,728 $6,421 

Note 16. EQUITY

The following table summarizes changes in equity during the nine months ended September 30, 2024:
Common StockCapital in Excess of Par Value of StockAccumulated Other Comprehensive LossRetained EarningsTreasury StockNoncontrolling Interest
Dollars and shares in millionsSharesPar ValueSharesCost
Balance at December 31, 20232,923 $292 $45,684 $(1,546)$28,766 902 $(43,766)$55 
Net (loss)/earnings
— — — — (11,911)— — 3 
Other comprehensive income/(loss)
— — — 146 — — — — 
Cash dividends declared $0.60 per share
— — — — (1,215)— — — 
Stock compensation— — (29)— — (6)69 — 
Balance at March 31, 20242,923 $292 $45,655 $(1,400)$15,640 896 $(43,697)$58 
Net earnings— — — — 1,680 — — 4 
Other comprehensive income/(loss)
— — — (56)— — — — 
Cash dividends declared $0.60 per share
— — — — (1,217)— — — 
Stock compensation— — 111 — — — 7 — 
Distributions— — — — — — — (8)
Balance at June 30, 20242,923 $292 $45,766 $(1,456)$16,103 896 $(43,690)$54 
Net earnings
— — — — 1,211 — — 4 
Other comprehensive income/(loss)
— — — (12)— — — — 
Cash dividends declared $0.60 per share
— — — — (1,217)— — — 
Stock repurchase program— — — — — — — — 
Stock compensation— — 130 — — (1)15 — 
Balance at September 30, 2024
2,923 $292 $45,896 $(1,468)$16,097 895 $(43,675)$58 

The following table summarizes changes in equity during the nine months ended September 30, 2023:
25

Common StockCapital in Excess of Par Value of StockAccumulated Other Comprehensive LossRetained EarningsTreasury StockNoncontrolling Interest
Dollars and shares in millionsSharesPar ValueSharesCost
Balance at December 31, 20222,923 $292 $45,165 $(1,281)$25,503 825 $(38,618)$57 
Net earnings— — — — 2,262 — — 5 
Other comprehensive income/(loss)
— — — (87)— — — — 
Cash dividends declared $0.57 per share
— — — — (1,197)— — — 
Share repurchase program— — — — — 4 (250)— 
Stock compensation— — (25)— — (6)60 — 
Balance at March 31, 20232,923 $292 $45,140 $(1,368)$26,568 823 $(38,808)$62 
Net earnings— — — — 2,073 — — 4 
Other comprehensive income/(loss)
— — — (19)— — — — 
Cash dividends declared $0.57 per share
— — — — (1,192)— — — 
Share repurchase program
— — — — — 13 (911)— 
Stock compensation— — 159 — — (2)39 — 
Distributions— — — — — — — (9)
Balance at June 30, 20232,923 $292 $45,299 $(1,387)$27,449 834 $(39,680)$57 
Net earnings
— — — — 1,928 — — 7 
Other comprehensive income/(loss)
— — — 101 — — — — 
Cash dividends declared $0.57 per share
— — — — (1,159)— — — 
Share repurchase program
— — (600)— — 56 (3,433)— 
Stock compensation— — 146 — — (1)27 — 
Convertible debt
— — 4 — — — 11 — 
Balance at September 30, 20232,923 $292 $44,849 $(1,286)$28,218 889 $(43,075)$64 

During the third quarter of 2023, BMS entered into accelerated share repurchase ("ASR") agreements to repurchase an aggregate amount of $4.0 billion of the Company's common stock. Approximately 56 million shares of common stock (85% of the 4.0 billion aggregate repurchase price) were received by BMS and included in treasury stock as of September 30, 2023. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $1.2 billion during the nine months ended September 30, 2023.

26

The following table summarizes the changes in Other comprehensive income by component:
Three Months Ended September 30, 2024Nine Months Ended September 30, 2024
Dollars in millionsPretaxTaxAfter TaxPretaxTaxAfter Tax
Derivatives qualifying as cash flow hedges
Recognized in other comprehensive income/(loss)
$(159)$26 $(133)$179 $(33)$146 
Reclassified to net earnings(a)
(58)13 (45)(93)14 (79)
Derivatives qualifying as cash flow hedges(217)39 (178)86 (19)67 
Pension and postretirement benefits
Actuarial gains/(losses)4 — 4 (89)22 (67)
Amortization(b)
4 (1)3 7 (1)6 
Settlements(b)
100 (7)93 119 (9)110 
Pension and postretirement benefits108 (8)100 37 12 49 
Marketable debt securities
Unrealized gains/(losses)
7 (2)5 4 (1)3 
Foreign currency translation34 27 61 (47)6 (41)
Other comprehensive income/(loss)$(68)$56 $(12)$80 $(2)$78 

Three Months Ended September 30, 2023
Nine Months Ended September 30, 2023
Dollars in millionsPretaxTaxAfter TaxPretaxTaxAfter Tax
Derivatives qualifying as cash flow hedges
Recognized in other comprehensive income/(loss)
$150 $(18)$132 $231 $(31)$200 
Reclassified to net earnings(a)
(16)(2)(18)(235)28 (207)
Derivatives qualifying as cash flow hedges134 (20)114 (4)(3)(7)
Pension and postretirement benefits
Actuarial gains/(losses)3 (1)2 (10)1 (9)
Marketable debt securities
Unrealized gains/(losses)(3)1 (2)(3)1 (2)
Foreign currency translation4 (17)(13)35 (22)13 
Other comprehensive income/(loss)$138 $(37)$101 $18 $(23)$(5)
(a)Included in Cost of products sold and Other (income)/expense, net. Refer to "—Note 9. Financial Instruments and Fair Value Measurements" for further information.
(b)Included in Other (income)/expense, net.

The accumulated balances related to each component of Other comprehensive (loss)/income, net of taxes, were as follows:
Dollars in millionsSeptember 30,
2024		December 31,
2023
Derivatives qualifying as cash flow hedges$69 $2 
Pension and postretirement benefits(689)(738)
Marketable debt securities5 2 
Foreign currency translation(a)
(853)(812)
Accumulated other comprehensive loss$(1,468)$(1,546)
(a)Includes net investment hedge gains of $126 million and $144 million as of September 30, 2024 and December 31, 2023, respectively.

27

Note 17. EMPLOYEE STOCK BENEFIT PLANS

Stock-based compensation expense was as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Cost of products sold$14 $14 $42 $38 
Marketing, selling and administrative53 55 154 162 
Research and development62 63 191 191 
Total stock-based compensation expense
$129 $132 $387 $391 
Income tax benefit(a)
$27 $28 $82 $80 
(a)    Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $(4) million and $(24) million for the three and nine months ended September 30, 2024, and $1 million and $21 million for the three and nine months ended September 30, 2023, respectively.

The number of units granted and the weighted-average fair value on the grant date for the nine months ended September 30, 2024 were as follows:
Units in millionsUnitsWeighted-Average Fair Value
Restricted stock units13.3 $47.42 
Market share units1.3 $58.63 
Performance share units1.9 $53.08 
Dollars in millionsRestricted Stock UnitsMarket Share UnitsPerformance Share Units
Unrecognized compensation cost$908 $76 $101 
Expected weighted-average period in years of compensation cost to be recognized2.72.31.9

Note 18. LEGAL PROCEEDINGS AND CONTINGENCIES

BMS and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, partners, suppliers, service providers, licensees, licensors, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that BMS believes could become significant or material are described below.

While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial claims and/or defenses in the matters, the outcomes of BMS's legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that there will not be an increase in the scope of one or more of these pending matters or any other or future lawsuits, claims, government investigations or other legal proceedings will not be material to BMS's financial position, results of operations or cash flows for a particular period. Furthermore, failure to successfully enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition.

Unless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably estimated. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS’s tax contingencies, see " —Note 7. Income Taxes."

INTELLECTUAL PROPERTY

Eliquis - Europe
Lawsuits have been filed by generic companies in various countries in Europe seeking revocation of our composition-of-matter patents and SPCs relating to Eliquis, and trials or preliminary proceedings have been held in certain of those cases.

28

In Belgium, BMS filed infringement proceedings against Sandoz in February 2024. A hearing date in these proceedings has been scheduled for November 2024.

In Croatia, in February 2024, the court granted BMS's request for a preliminary injunction to prohibit Teva from offering, storing or selling generic Eliquis products in Croatia. Teva appealed this decision. On July 24, 2024, Teva's appeal was rejected by the Croatian Court of Appeal.

In Finland, the court granted our request for a preliminary injunction prohibiting Teva from offering, storing or selling generic Eliquis products in Finland that have obtained price and reimbursement. A trial regarding Teva's challenge to the validity of the Finnish composition-of-matter patent and related SPC concluded on July 5, 2023. On May 22, 2024, the Finnish court held the patent to be invalid and lifted the preliminary injunction. BMS has sought permission to appeal this decision. Teva and Sandoz have both launched generic apixaban products on the Finnish market.

In France, a trial was held regarding Teva's challenge to the validity of the French composition-of-matter patent and related SPC, and a decision was issued on June 8, 2023, confirming their validity and rejecting Teva's claims. Teva has appealed the decision and a hearing of the appeal has been scheduled for November 2025.

In Ireland, the court granted our request for a preliminary injunction prohibiting Teva from making, offering, putting on the market and/or using and/or importing or stocking for the aforesaid purposes, generic Eliquis products. The trial court's preliminary injunction decision was subsequently affirmed on appeal by the Irish Court of Appeal. In a decision delivered on December 8, 2023, the Irish trial court found the Irish composition-of-matter patent and related SPC to be invalid. BMS appealed the Irish trial court's decision. On June 13, 2024, the Irish Court of Appeal entered an injunction restraining Teva from launching its generic product pending the determination of BMS's appeal of the trial court's invalidity decision.

In the Netherlands, our requests for preliminary injunctions to prevent at-risk generic launches by Sandoz, Stada and Teva prior to full trials on the validity of the Dutch composition-of-matter patent and SPC were initially denied by the lower courts. However, in a judgment issued on August 15, 2023, the Dutch Court of Appeal overturned the decisions of the lower court, issued preliminary injunctions against Sandoz, Stada and Teva and ordered those companies to recall any generic Eliquis product from the Dutch market. Trials regarding challenges brought by Sandoz and Teva, respectively, to the validity of the Dutch composition-of-matter patent and related SPC took place on October 13, 2023 and January 12, 2024. On October 30, 2024, the district court issued decisions confirming the validity of the Dutch composition-of-matter patent and SPC.

In Norway, a trial was held regarding Teva's challenge to the validity of the Norwegian composition-of-matter patent and related SPC, and a decision was issued on May 23, 2023, confirming their validity and rejecting Teva's claims. Teva appealed the decision, and on June 3, 2024, the Court of Appeal issued a decision confirming the validity of the patent and related SPC. Teva is seeking permission to appeal the decision from the Supreme Court of Norway.

In Portugal, there are patent validity and infringement proceedings pending with multiple companies seeking to market generic versions of Eliquis. A trial regarding Mylan's challenge to the validity of the Portuguese composition-of-matter patent concluded in the second quarter of 2024 and a decision is pending. In early September 2023, Teva launched a generic Eliquis product on the Portuguese market. On September 15, 2023, the Company filed a request for a preliminary injunction against Teva at the Portuguese Intellectual Property Court. The hearing of the preliminary injunction against Teva concluded in the second quarter of 2024 and a decision is pending.

In Romania, our request for a preliminary injunction against Teva was initially denied by the lower court. However, in January 2024, the Romania Court of Appeal overturned the decision of the lower court, and issued a preliminary injunction against Teva prohibiting Teva from offering, storing or selling generic Eliquis products in Romania.

In Spain, a trial regarding Teva's challenge to the validity of the Spanish composition-of-matter patent and related SPC was held on October 18-19, 2023, and in a decision delivered in January 2024, the Barcelona Commercial Court found the Spanish composition-of-matter patent and related SPC to be invalid. BMS appealed the decision of the Barcelona Commercial Court to the Barcelona Court of Appeal. In February 2024, the Madrid Commercial Court granted BMS’s preliminary injunctions against Teva, Sandoz and Normon pending determination of the appeal of the decision of the Barcelona Commercial Court. Teva sought an order from the Barcelona Commercial Court to effectively overturn the preliminary injunction. BMS then sought and was granted an order from the Madrid Commercial Court requiring Teva to comply with the preliminary injunction. The issue was referred to the Spanish Supreme Court, which on April 26, 2024 issued a judgment requiring the Madrid Commercial Court to lift the injunction in place against Teva. On July 16, 2024, the Madrid Commercial Court issued a decision maintaining the preliminary injunctions against Sandoz and Normon. In a decision dated July 18, 2024, the Barcelona Court of Appeal overturned the decision of the Barcelona Commercial Court and upheld the validity of the Spanish composition-of-matter patent and related SPC.

29

In Sweden, a trial was held regarding Teva's challenge to the validity of the Swedish composition-of-matter patent and related SPC, and a decision was issued on November 2, 2022, confirming their validity and rejecting Teva's claims. Teva appealed the decision, and the appeal was heard in May 2024. On June 20, 2024, the Court of Appeal issued a decision upholding the validity of the patent and related SPC.

In Switzerland, a trial was held regarding Teva's challenge to the validity of the Swiss composition-of-matter patent and related SPC, and a decision was issued on March 8, 2024, confirming their validity and rejecting Teva's claims. Teva appealed the decision, but on October 4, 2024, the Federal Supreme Court issued a decision upholding the validity of the patent and related SPC.

In the UK, Sandoz and Teva filed lawsuits seeking revocation of the UK composition-of-matter patent and related SPC. BMS subsequently filed counterclaims for infringement in both actions. A combined trial took place in February 2022, and in a judgment issued on April 7, 2022, the judge found the UK apixaban composition-of-matter patent and related SPC invalid. BMS appealed the judgment and on May 4, 2023, the Court of Appeal upheld the lower court's decision. On October 31, 2023, the UK Supreme Court rejected BMS's application to appeal. Following the first instance decision in the UK, generic manufacturers have begun marketing generic versions of Eliquis in the UK.

In Czechia, Teva filed an action seeking revocation of the Czech composition of matter patent and related SPC. On July 25, 2024, the Czech Intellectual Property Office issued a decision holding the patent and SPC to be valid. Teva has appealed this decision.

In Slovakia, Teva filed an action seeking revocation of the Slovak composition of matter patent and related SPC. On August 22, 2024, the Slovak Intellectual Property Office issued a decision holding the patent and SPC to be invalid. BMS intends to appeal the decision.

In addition to the above, challenges to the validity of the composition-of-matter patent and related SPC are pending in Denmark, Italy, Poland, Hungary, Bulgaria, Greece and Lithuania.

Generic manufacturers may seek to market generic versions of Eliquis in additional countries in Europe prior to the expiration of our patents, which may lead to additional infringement and invalidity actions involving Eliquis patents being filed in various countries in Europe.

Plavix* - Australia
Sanofi was notified that, in August 2007, GenRx Proprietary Limited ("GenRx") obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex ("GenRx-Apotex"). In August 2007, GenRx-Apotex filed an application in the Federal Court of Australia seeking revocation of Sanofi's Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi's injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the GenRx-Apotex case. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia ("Full Court") appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($310 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi dispute that the Australian government is entitled to any damages. A trial was concluded in September 2017. In April 2020, the Federal Court issued a decision dismissing the Australian government's claim for damages. In May 2020, the Australian government appealed the Federal Court's decision and an appeal hearing concluded in February 2021. On June 26, 2023, the appeal court issued a ruling in BMS and Sanofi's favor, upholding the lower court's decision. In December 2023, the Australian government was granted leave to appeal the decision to the High Court of Australia, and the High Court held an appeal hearing on September 4-5, 2024, and a decision is pending.

Zeposia - U.S.
On October 15, 2021, Actelion Pharmaceuticals LTD and Actelion Pharmaceuticals US, INC ("Actelion") filed a complaint for patent infringement in the United States District Court for the District of New Jersey against BMS and Celgene for alleged infringement of U.S. Patent No. 10,251,867 (the "'867 Patent"). The Complaint alleges that the sale of Zeposia infringes certain claims of the '867 Patent and Actelion is seeking damages. No trial date has been scheduled.

30

In May and June 2024, BMS received Notice Letters from Synthon BV ("Synthon") and Apotex Inc. ("Apotex"), respectively, each notifying BMS that it has filed an ANDA containing a paragraph IV certification seeking approval of a generic version of Zeposia in the U.S. and challenging a U.S. patent listed in the Orange Book for Zeposia. In response, BMS filed patent infringement actions against Synthon and Apotex in the U.S. District Court for the District of Delaware. On August 14, 2024 and September 16, 2024, Synthon and Apotex answered their respective complaints. On September 23, 2024, the district court consolidated the Synthon and Apotex actions. No trial date has been scheduled.

PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION

Plavix* State Attorneys General Lawsuits
BMS and certain Sanofi entities are defendants in a consumer protection action brought by the attorney general of Hawaii relating to the labeling, sales and/or promotion of Plavix*. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $834 million, with $417 million attributed to BMS. Sanofi and BMS appealed the decision. On March 15, 2023, the Hawaii Supreme Court issued its decision, reversing in part and affirming in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. A new bench trial concluded on October 16, 2023. On May 21, 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $916 million, with $458 million attributed to BMS. Sanofi and BMS have appealed the decision.

PRODUCT LIABILITY LITIGATION

BMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, BMS also faces unfiled claims involving its products.

Abilify*
BMS and Otsuka are co-defendants in product liability litigation related to Abilify*. Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. Cases were filed in state and federal courts in the United States. Pursuant to a previously disclosed master settlement agreement and settlement related court orders, the vast majority of the cases in the United States were resolved or dismissed. Eleven inactive cases remain pending in state courts in New Jersey. There are also eleven cases pending in Canada (four class actions and seven individual injury claims), two of which are active (the certified class actions in Quebec and Ontario). A settlement in principle has recently been reached in the class actions, subject to Court approval.

SECURITIES LITIGATION

Celgene Securities Litigations
Beginning in March 2018, two putative class actions were filed against Celgene and certain of its officers in the U.S. District Court for the District of New Jersey (the "Celgene Securities Class Action"). The complaints allege that the defendants violated federal securities laws by making misstatements and/or omissions concerning (1) trials of GED-0301, (2) Celgene's 2020 outlook and projected sales of Otezla*, and (3) the NDA for Zeposia. The Court consolidated the two actions and appointed a lead plaintiff, lead counsel, and co-liaison counsel for the putative class. In February 2019, the defendants filed a motion to dismiss plaintiffs' amended complaint in full. In December 2019, the Court denied the motion to dismiss in part and granted the motion to dismiss in part (including all claims arising from alleged misstatements regarding GED-0301). Although the Court gave the plaintiff leave to re-plead the dismissed claims, it elected not to do so, and the dismissed claims are now dismissed with prejudice. In November 2020, the Court granted class certification with respect to the remaining claims. In March 2023, the Court granted the defendants leave to file a motion for summary judgment, the briefing for which was completed in June 2023. On September 8, 2023, the Court granted in part and denied in part defendants' motion for summary judgment as to the claims regarding statements made by the remaining officer defendants. As to the claims regarding Celgene’s corporate statements, the Court denied the defendants’ motion without prejudice and granted the defendants leave to re-raise the issue. On October 27, 2023, the defendants filed a motion for partial summary judgment as to Celgene’s corporate statements. On July 23, 2024, the Court granted the defendants’ motion as to individual liability for those corporate statements but reserved decision as to the company's liability, noting that another opinion would be forthcoming. On September 4, 2024, the Court granted in part, denied in part, and held in abeyance in part the defendants’ motion for summary judgment as to the Company’s liability for Celgene’s corporate statements and requested supplemental briefing as to the statements the Court did not rule on. Following supplemental briefing, the Court held a hearing on October 10, 2024, where it denied defendants' summary judgment motion as to the remaining statements at issue.

In April 2020, certain Schwab management investment companies on behalf of certain Schwab funds filed an individual action in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action against the same remaining defendants in that action (the "Schwab Action"). In July 2020, the defendants filed a motion to dismiss the plaintiffs' complaint in full. In March 2021, the Court granted in part and denied in part defendants' motion to dismiss consistent with its decision in the Celgene Securities Class Action.
31


The California Public Employees' Retirement System in April 2021 (the "CalPERS Action"); DFA Investment Dimensions Group Inc., on behalf of certain of its funds; and American Century Mutual Funds, Inc., on behalf of certain of its funds, in July 2021 (respectively, the "DFA Action" and the "American Century Action"), and GIC Private Limited in September 2021 (the "GIC Action"), filed separate individual actions in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action and the Schwab individual action against the same remaining defendants in those actions. In October 2021, these actions were consolidated for pre-trial proceedings with the Schwab Action. The Court also consolidated any future direct actions raising common questions of law and fact with the Schwab Action (the "Consolidated Schwab Action"). On October 2, 2023, defendants filed a motion for partial summary judgment in the Consolidated Schwab Action. The motion is fully briefed and currently pending before the Court.

No trial dates have been scheduled in any of the above Celgene Securities Litigations.

Contingent Value Rights Litigations
In June 2021, an action was filed against BMS in the U.S. District Court for the Southern District of New York asserting claims of alleged breaches of a Contingent Value Rights Agreement ("CVR Agreement") entered into in connection with the closing of BMS's acquisition of Celgene in November 2019. An entity claiming to be the successor trustee under the CVR Agreement alleged that BMS breached the CVR Agreement by allegedly failing to use "diligent efforts" to obtain FDA approval of liso-cel (Breyanzi) before a contractual milestone date, thereby allegedly avoiding a $6.4 billion potential obligation to holders of the contingent value rights governed by the CVR Agreement and by allegedly failing to permit inspection of records in response to a request by the alleged successor trustee. The plaintiff sought damages in an amount to be determined at trial and other relief, including interest and attorneys' fees. BMS disputes the allegations. BMS filed a motion to dismiss the alleged successor trustee's complaint for failure to state a claim upon which relief can be granted, which was denied on June 24, 2022. On February 2, 2024, BMS filed a motion to dismiss the complaint for lack of subject matter jurisdiction. In an opinion and order entered on September 30, 2024, the court granted BMS’s motion and dismissed the lawsuit for lack of subject matter jurisdiction without prejudice to the refiling of a new lawsuit by a properly appointed trustee. The plaintiff has appealed this order.

In October 2021, alleged former Celgene stockholders filed a complaint in the U.S. District Court for the Southern District of New York asserting claims on behalf of a putative class of Celgene stockholders who received CVRs in the BMS merger with Celgene for violations of sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") relating to the joint proxy statement. That action later was consolidated with another action filed in the same court, and a consolidated complaint thereafter was filed asserting claims on behalf of a class of CVR acquirers, whether in the BMS merger with Celgene or otherwise, for violations of sections 11, 12(a)(2), and 15 of the Securities Act of 1933 (the "Securities Act") and sections 10(b), 14(a) and 20(a) of the Exchange Act. The complaint alleged that the February 22, 2019 joint proxy statement was materially false or misleading because it failed to disclose that BMS allegedly had no intention to obtain FDA approval for liso-cel (Breyanzi) by the applicable milestone date in the CVR Agreement and that certain statements made by BMS or certain BMS officers in periodic SEC filings, earnings calls, press releases, and investor presentations between December 2019 and November 2020 were materially false or misleading for the same reason. Defendants moved to dismiss the complaint. On March 1, 2023, the Court entered an opinion and order granting defendants' motion and dismissed the complaint in its entirety. The claims under Sections 11, 12(a)(2), and 15 of the Securities Act and Section 14(a) of the Exchange Act were dismissed with prejudice. The claims under Sections 10(a) and 20(a) of the Exchange Act were dismissed with leave to file a further amended complaint, which plaintiffs filed on April 14, 2023. Defendants moved to dismiss the amended complaint and briefing on the motion was completed on June 23, 2023. In an opinion and order entered on February 29, 2024, the Court granted that motion in its entirety and dismissed the remaining claims with prejudice. On March 28, 2024, plaintiffs filed a notice of appeal. Briefing has been completed in the appeal, which is pending in the United States Court of Appeals for the Second Circuit. Oral argument took place on October 25, 2024.

In November 2021, an alleged purchaser of CVRs filed a complaint in the Supreme Court of the State of New York for New York County asserting claims on behalf of a putative class of CVR acquirers for violations of sections 11(a) and 12(a)(2) of the Securities Act of 1933. The complaint alleged that the registration statement filed in connection with the proposed merger transaction between Celgene and BMS was materially false or misleading because it failed to disclose that allegedly BMS had no intention at the time to obtain FDA approval for liso-cel (Breyanzi) by the contractual milestone date. The complaint asserted claims against BMS, the members of its board of directors at the time of the joint proxy statement, and certain BMS officers who signed the registration statement. Defendants moved to stay the action pending resolution of the federal action or, in the alternative, to dismiss the complaint and later filed a similar motion in response to an amended complaint. On February 2, 2024, the Court granted defendants’ motion and dismissed the case in its entirety. On February 29, 2024, the plaintiff filed a notice of appeal. The plaintiff’s appeal was not perfected before the deadline for doing so under applicable court rules, and therefore, the appeal is deemed to be dismissed under those rules.

32

In November 2021, an alleged Celgene stockholder filed a complaint in the Superior Court of New Jersey, Union County asserting claims on behalf of two separate putative classes, one of acquirers of CVRs and one of acquirers of BMS common stock, for violations of sections 11(a), 12(a)(2), and 15 of the Securities Act. The complaint alleges that the registration statement filed in connection with the proposed merger transaction between Celgene and BMS was materially false or misleading because it failed to disclose that allegedly BMS had no intention at the time to obtain FDA approval for liso-cel (Breyanzi) by the contractual milestone date. The complaint asserts claims against BMS, the members of its board of directors at the time of the joint proxy statement, certain BMS officers who signed the registration statement and Celgene's former chairman and chief executive officer. The Court had temporarily stayed the action pending resolution of the federal action, but lifted the stay on March 21, 2024, following the dismissal of the federal action. On April 4, 2024, defendants moved to dismiss the New Jersey complaint. On June 25, 2024, the Court granted defendants' motion and dismissed the complaint in its entirety without prejudice. The plaintiff filed an amended complaint on August 15, 2024. On September 30, 2024, the defendants filed a motion to dismiss the amended complaint.

No trial dates have been scheduled in any of the above CVR Litigations.

OTHER LITIGATION

IRA Litigation
On June 16, 2023, BMS filed a lawsuit against the U.S. Department of Health & Human Services and the Centers for Medicare & Medicaid Services, et al., challenging the constitutionality of the drug-pricing program in the IRA. That program requires pharmaceutical companies, like BMS, under the threat of significant penalties, to sell certain of their medicines at government-dictated prices. On August 29, 2023, the government selected Eliquis for this program. In its lawsuit, BMS argues that this program violates the Fifth Amendment, which requires the government to pay just compensation if it takes property for public use, by requiring pharmaceutical manufacturers to provide medicines to third parties at prices set by the government that necessarily fall below fair market value. BMS also argues that this program violates the First Amendment right to free speech by requiring manufacturers to state that they agree that the price set by the government is the medicine's "maximum fair price" as determined by negotiation, even though there is no true negotiation. On August 16, 2023, BMS filed a motion for summary judgment. On October 16, 2023, the government filed an opposition to BMS’s motion for summary judgment and a cross-motion for summary judgment. The court heard oral argument on the parties' summary judgment motions on March 7, 2024. On April 29, 2024, the court issued an opinion and order that denied BMS's motion for summary judgment and granted the government's cross-motion for summary judgment. BMS appealed to the United States Court of Appeals for the Third Circuit. Oral argument in the Third Circuit took place on October 30, 2024.

Thalomid and Revlimid Litigations
Beginning in November 2014, certain putative class action lawsuits were filed against Celgene in the U.S. District Court for the District of New Jersey alleging that Celgene violated various antitrust, consumer protection, and unfair competition laws by (a) allegedly securing an exclusive supply contract for the alleged purpose of preventing a generic manufacturer from securing its own supply of thalidomide active pharmaceutical ingredient, (b) allegedly refusing to sell samples of Thalomid and Revlimid brand drugs to various generic manufacturers for the alleged purpose of bioequivalence testing necessary for ANDAs to be submitted to the FDA for approval to market generic versions of these products, (c) allegedly bringing unjustified patent infringement lawsuits in order to allegedly delay approval for proposed generic versions of Thalomid and Revlimid, and/or (d) allegedly entering into settlements of patent infringement lawsuits with certain generic manufacturers that allegedly have had anticompetitive effects. The plaintiffs, on behalf of themselves and putative classes of third-party payers, sought injunctive relief and damages. The various lawsuits were consolidated into a master action for all purposes. In March 2020, Celgene reached a settlement with the class plaintiffs. In October 2020, the Court entered a final order approving the settlement and dismissed the matter. That settlement did not resolve certain claims of certain entities that opted out of the settlement, and who have since filed new suits advancing related theories. As described below, certain other consolidated or coordinated suits are pending.

In March 2019, Humana Inc. ("Humana"), which opted out of the above settlement, filed a lawsuit against Celgene in the U.S. District Court for the District of New Jersey. Humana's complaint makes largely the same claims and allegations as were made in the now settled Thalomid and Revlimid antitrust class action litigation. The complaint purports to assert claims on behalf of Humana and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys' fees and costs. In May 2019, Celgene filed a motion to dismiss Humana's complaint. In April 2022, the Court issued an order denying Celgene's motion to dismiss. That order addressed only Celgene's argument that certain of Humana's claims were barred by the statute of limitations. The Court's order did not address Celgene's other grounds for dismissal and instead directed Celgene to present those arguments in a renewed motion to dismiss following the filing of amended complaints. In May 2022, Humana filed an amended complaint against Celgene and BMS asserting the same claims based on additional factual allegations. Celgene and BMS subsequently filed a motion to dismiss Humana's amended complaint. On August 18, and September 8, 2023, the Court held argument on Celgene and BMS' motion. On June 6, 2024, the Court granted Celgene and BMS's motion to dismiss in its entirety. The Court granted Humana and the other plaintiffs referenced immediately below (other than United HealthCare Services Inc. ("UHS"), which had previously amended) leave to amend their complaints. These plaintiffs filed amended complaints on August 5, 2024.
33


UHS, Blue Cross Blue Shield Association ("BCBSM"), BCBSM Inc., Health Care Service Corporation ("HCSC"), Blue Cross and Blue Shield of Florida Inc., Cigna Corporation ("Cigna"), Molina Healthcare, Inc. ("Molina") and several MSP related entities (MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, "MSP")) filed lawsuits between 2020 and 2022 making largely the same claims and allegations as were made in the now-settled class action litigation and in the Humana opt-out action. The UHS and MSP matters include additional claims related to copay assistance for Thalomid and Revlimid. These cases are now pending in the U.S. District Court for the District of New Jersey. BCBSM has voluntarily dismissed its claims. The Court's order granting Celgene and BMS's motion to dismiss in the Humana action dismissed the complaints filed by these plaintiffs as well (except as to UHS, which has already been amended). The Court granted these plaintiffs leave to amend all dismissed claims, with the exception of MSP's claims under RICO, which were dismissed with prejudice. These plaintiffs filed amended complaints on August 5, 2024.

In May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the now settled class action litigation. In June 2022, the San Francisco Superior Court dismissed 63 of Molina’s claims, which Molina later reasserted in the District of New Jersey as described above, and stayed the remaining 4 claims. No activity is expected in this case until disposition of the New Jersey actions.

Certain other entities that opted out of the now‑settled class action have also filed summonses related to two actions in the Philadelphia County Court of Common Pleas in connection with the allegations made by Humana and other opt‑out entities. Those actions have been placed in deferred status pending further developments in the above opt‑out cases.

In November 2022, certain specialty pharmacies filed an action as direct purchasers against Celgene, BMS, and certain generic manufacturers in the U.S. District Court for the District of New Jersey. The action makes largely the same claims and allegations against Celgene and BMS as were made with respect to Revlimid in the now settled class action litigation, and seeks injunctive relief and damages under the Sherman Antitrust Act. Also in November 2022, a putative class of end-payor plaintiffs filed an action against Celgene, BMS, and certain generic manufacturers in the U.S. District Court for the District of New Jersey. The class complaint brings claims based on Celgene's allegedly anticompetitive settlements of Revlimid patent litigation, seeking damages under state antitrust and consumer protection laws and injunctive relief under federal antitrust law. Celgene, BMS and the generic defendants have filed consolidated motions to dismiss these two actions. The motions were fully briefed in May 2023 and administratively terminated in November 2023 pending a ruling on Celgene and BMS's motion to dismiss the Humana amended complaint. In view of the Court's dismissal decision in the Humana action described above, these plaintiffs filed amended complaints on August 5, 2024.

In October and November 2023, three healthcare systems—the Mayo Clinic, LifePoint Corporate Services, G.P. and Intermountain Health, Inc.—filed two new lawsuits against Celgene, BMS and certain generic manufacturers making largely the same claims and allegations against Celgene and BMS as were made with respect to Revlimid in the now-settled class action litigation, and seeking injunctive relief and damages under the Sherman Antitrust Act and parallel state laws. In view of the Court's dismissal decision in the Humana action described above, these plaintiffs filed amended complaints on August 5, 2024. Those actions are pending in the U.S. District Court for the District of New Jersey.

No trial dates have been scheduled in any of the above Thalomid and Revlimid Litigations.

Pomalyst Antitrust Class Action
In September 2023, certain health plan entities filed an action on behalf of a putative class of end-payor plaintiffs against Celgene, BMS, and certain generic pharmaceutical manufacturers in the U.S. District Court for the Southern District of New York. The class complaint asserts claims under federal antitrust law and state antitrust, consumer protection, and unjust enrichment laws based on allegations that Celgene and BMS engaged in anticompetitive conduct related to pomalidomide in the U.S., including by allegedly engaging in fraud before the USPTO in the acquisition of patents related to the use of pomalidomide, by filing alleged sham patent litigations against generic pharmaceutical companies seeking to market generic pomalidomide, and by entering into allegedly unlawful patent litigation settlements with certain generic pharmaceutical companies seeking to market generic pomalidomide. In December 2023, the plaintiffs filed an amended complaint that added one individual Pomalyst patient as a plaintiff, removed the generic manufacturer defendants, and added two individuals as defendants. In March 2024, one new plaintiff filed a substantially similar complaint, on behalf of the same putative class and in the same court, which was subsequently consolidated with the first action. In March 2024, BMS and its co-defendants filed motions to dismiss these actions. In September 2024, an additional plaintiff (seeking to proceed solely as a direct purchaser under the federal antitrust laws) filed a separate, substantially similar complaint. No trial dates have been scheduled.

34

GOVERNMENT INVESTIGATIONS

Like other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.

ENVIRONMENTAL PROCEEDINGS

As previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.

CERCLA and Other Remediation Matters

With respect to CERCLA and other remediation matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other "potentially responsible parties," and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $78 million as of September 30, 2024, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.

35

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related footnotes included elsewhere in this Quarterly Report on Form 10-Q to enhance the understanding of our results of operations, financial condition and cash flows.

EXECUTIVE SUMMARY

Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry. Our priorities are to (i) focus on transformational medicines where we have a competitive advantage (ii) drive operational excellence and (iii) strategically allocate capital for long-term growth and returns. Our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases in the following core therapeutic areas: oncology and hematology with novel modalities in cell therapies, protein degraders, ADCs and radiopharmaceuticals; immunology with a focus on establishing new standards of care in pulmonology, rapidly advancing cell therapy into immunology diseases and transformational programs to control inflammation, reset immune memory and promote homeostasis in dermatology, rheumatology and gastrointestinal disorders; cardiovascular diseases by leveraging deep expertise across thrombotic diseases, heart failures and cardiomyopathies; and neuroscience with a focus on developing new treatments in neuropsychiatry and neurodegeneration. We are working on accelerating our drug development and delivery of our innovative medicines to patients, enhancing our commercial operating model, as well as enhancing flexibility and reliability of our manufacturing network. We remain committed to strategic business development, maintaining a strong investment grade credit rating, the dividend and reducing debt. For further information on our strategy, see "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations—Executive Summary—Strategy" in our 2023 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.

In September 2024, we received FDA approval for Cobenfy (xanomeline and trospium chloride), formerly known as KarXT, for the treatment of schizophrenia in adults, re-establishing our presence in neuroscience. Cobenfy represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies. Registrational studies are planned for Cobenfy in Adjunctive Schizophrenia, Alzheimer's Psychosis, Alzheimer's Agitation, Alzheimer's Cognition, Bipolar I Disorder and autism spectrum disorder irritability. In addition, year-to-date, we have achieved significant advances in CAR-T cell therapy with the approval of Breyanzi in the U.S. and Japan for adults with relapsed or refractory FL and in the U.S. for adults with relapsed or refractory CLL/SLL and MCL; and Abecma in the U.S. and EU for triple-class exposed relapsed and refractory multiple myeloma after two or more prior lines of therapy. Furthermore, Reblozyl received expanded approval to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk MDS in the EU and Japan. In oncology, we continue making advancements with (i) FDA approval of Opdivo for the treatment of adult patients with resectable NSCLC, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery; (ii) accelerated approval in the U.S. of Krazati in combination with cetuximab, for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer; (iii) approval in the U.S. of Augtyro for the treatment of patients with NTRK-positive locally advanced or metastatic solid tumors; (iv) approval in Japan of Augtyro for the treatment of patients with ROS1 fusion-positive, unresectable advanced or recurrent NSCLC; and (v) both in the U.S. and EU, approval of Opdivo in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic muscle invasive urothelial carcinoma. Refer to "—Product and Pipeline Developments" for additional updates on our pipeline.

Additionally, we completed the following acquisitions in 2024: (i) Karuna, a biopharmaceutical company in the area of developing and delivering medicines, including Cobenfy, for psychiatric and neurological conditions; (ii) RayzeBio, a clinical-stage radiopharmaceutical therapeutics company with a pipeline of potentially first-in-class and best-in-class drug development programs; and (iii) Mirati, a commercial stage targeted oncology company, with a commercialized medicine, Krazati, in addition to a pipeline of clinical and pre-clinical stage oncology assets. BMS also entered into a strategic collaboration with SystImmune, to co-develop and co-commercialize BL-B01D1, a bispecific topoisomerase inhibitor-based anti-body drug conjugate, which is currently being evaluated in a Phase I clinical trial for metastatic or unresectable NSCLC and is also in development for breast cancer and other tumor types. We also entered into a worldwide capacity reservation and supply agreement with Cellares for the manufacturing of CAR-T cell therapies. This agreement is expected to enable us to expand our manufacturing capacity through a platform that is scalable and has the potential to improve turnaround time. For additional information relating to our acquisitions, divestitures, licensing and other arrangements refer to "Item 1. Financial Statements—Note 3. Alliances" and "Item 1. Financial Statements—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements".

36

We remain committed to the strategic allocation of resources and investing in areas that maximize value and drive sustainable growth. We continue to execute a strategic productivity initiative that will drive approximately $1.5 billion in annual cost savings by the end of 2025, the majority of which are expected to be reinvested to fund innovation and drive growth. As a result, we are focusing resources on R&D programs with the potential to deliver the greatest return on investment, prioritizing investments in key growth brands, and optimizing operations across the organization. The exit costs resulting from these actions are included in our updated 2023 Restructuring Plan.

Financial Highlights
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions, except per share data2024202320242023
Total Revenues$11,892 $10,966 $35,958 $33,529 
Diluted earnings/(loss) per share
GAAP$0.60 $0.93 $(4.45)$2.99 
Non-GAAP1.80 2.00 (0.53)5.80 

Revenues increased by 8% during the third quarter of 2024 and 7% year-to-date due to the Growth Portfolio and Eliquis, partially offset by Sprycel due to generic erosion. Year-to-date was also partially offset by Revlimid.

The $0.33 decrease in GAAP EPS and the $0.20 decrease in non-GAAP EPS for the third quarter of 2024 were primarily driven by higher interest expense and a lower effective income tax rate in 2023, partially offset by higher revenues.

The $7.44 decrease in GAAP EPS year-to-date was primarily driven by higher one-time Acquired IPRD charges primarily from the Karuna asset acquisition and SystImmune collaboration ($6.28) and the impact of certain specified items, including intangible asset impairments, as well as the cash settlement of unvested stock awards, partially offset by higher revenues. After adjusting for specified items, the $6.33 decrease in non-GAAP EPS year-to-date was primarily due to the aforementioned Acquired IPRD charges, partially offset by higher revenues.

Our non-GAAP financial measures, including non-GAAP earnings and related EPS information, are adjusted to exclude specified items that represent certain costs, expenses, gains and losses and other items impacting the comparability of financial results. For further information and reconciliations relating to our non-GAAP financial measures refer to "—Non-GAAP Financial Measures."

Economic and Market Factors

Governmental Actions

As regulators continue to focus on prescription drugs, our products are facing increased pressures across the portfolio. These pressures stem from legislative and policy changes, including price controls, pharmaceutical market access, discounting, changes to tax and importation laws and other restrictions in the U.S., EU and other regions around the world. These pressures have resulted in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse, which can negatively impact our results of operations (including intangible asset impairment charges), operating cash flow, liquidity and financial flexibility. The IRA directs (i) the federal government to “negotiate” prices for select high-cost Medicare Part D (beginning in 2026) and Part B (beginning in 2028) drugs that are more than nine years (for small-molecule drugs) or 13 years (for biological products) from their FDA approval, (ii) manufacturers to pay a rebate for Medicare Part B and Part D drugs when prices increase faster than inflation and (iii) Medicare Part D redesign replacing the current Part D CGDP and establishes a $2,000 cap for out-of-pocket costs for Medicare beneficiaries beginning in 2025, with manufacturers being responsible for 10% of costs up to the $2,000 cap and 20% after that cap is reached. In August 2024, as part of the first round of government price setting pursuant to the IRA, the U.S. Department of Health and Human Services announced the "maximum fair price" for a 30-day equivalent supply of Eliquis, which applies to the U.S. Medicare channel effective January 1, 2026. It is possible that more of our products could be selected in future years, which could, among other things, accelerate revenue erosion prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our results of operations and it is possible that these changes may result in a material impact on our business and results of operations.

In addition, in December 2023, the Biden Administration released a proposed framework that for the first time proposed that a drug’s price can be a factor in determining that the drug is not accessible to the public and therefore that the government could exercise “march-in rights” and license it to a third party to manufacture. We cannot predict whether the Biden Administration will finalize the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights or if the government will propose other drug pricing policy changes. If pursued and finalized, these policies could reduce prices and reimbursement for certain of our products and could significantly impact our business and consolidated results of operations.
37


At the state level, multiple states have passed, are pursuing or are considering government action via legislation or regulations to change drug pricing and reimbursement (e.g., establishing prescription drug affordability boards, implementing manufacturer mandates tied to the Federal Public Health Service Act drug pricing program, etc.). Some of these state-level actions may also influence federal and other state policies and legislation. Given the current uncertainty surrounding the adoption, timing and implementation of many of these measures, as well as pending litigation challenging such laws, we are unable to predict their full impact on our business. However, such measures could modify or decrease access, coverage, or reimbursement of our products, or result in significant changes to our sales or pricing practices, which could have a material impact on our revenues and results of operations. With respect to the Federal Public Health Service Act drug pricing program, eight states have enacted laws regulating manufacturer pricing obligations under the program to date. Several additional states are considering similar potential legislation or other government actions, and we expect other states may do the same in the future.

Additionally, in connection with the IRA, the following changes have been made to U.S. tax laws, including (i) a 15% minimum tax that generally applies to U.S. corporations on adjusted financial statement income beginning in 2023 and (ii) a non-deductible 1% excise tax provision on net stock repurchases, to be applied to repurchases beginning in 2023. Furthermore, countries are in the process of enacting changes to their tax laws to implement the agreement by the OECD to establish a global minimum tax. See risk factors on these items included under "Part I—Item 1A. Risk Factors—Product, Industry and Operational Risks—Increased pricing pressure and other restrictions in the U.S. and abroad continue to negatively affect our revenues and profit margins" and "—Changes to tax regulations could negatively impact our earnings" in our 2023 Form 10-K.

Significant Product and Pipeline Approvals

The following is a summary of the significant approvals received in 2024 as of October 31, 2024:
ProductDateApproval
Opdivo
October 2024
FDA approval of Opdivo for the treatment of adult patients with resectable (tumors ≥ 4 cm or node positive) NSCLC and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery.
Cobenfy
(KarXT; xanomeline and trospium chloride)
September 2024
FDA approval of Cobenfy for the treatment of schizophrenia in adults.
Augtyro
September 2024
Japan's Ministry of Health, Labour and Welfare approval of Augtyro for the treatment of patients with ROS1 fusion-positive, unresectable advanced or recurrent NSCLC.
Breyanzi
August 2024
Japan's Ministry of Health, Labour and Welfare approval of Breyanzi for the treatment of relapsed or refractory FL after one prior line of systemic therapy in patients with high-risk FL and after two or more lines of systemic therapy.
Krazati
June 2024
FDA accelerated approval for Krazati in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
Augtyro
June 2024
FDA accelerated approval of Augtyro for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.
38

Opdivo
May 2024
EC approval of Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
Breyanzi
May 2024
FDA approval of Breyanzi for the treatment of adult patients with relapsed or refractory MCL who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.
Breyanzi
May 2024
FDA accelerated approval of Breyanzi for the treatment of adult patients with relapsed or refractory FL who have received at least two prior lines of systemic therapy.
Abecma April 2024
FDA approval of Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Reblozyl
April 2024
EC expanded approval of Reblozyl to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk MDS.
Abecma
March 2024
EC approval of Abecma for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Breyanzi
March 2024
FDA accelerated approval of Breyanzi for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor.
Opdivo
March 2024
FDA approval of Opdivo, in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
Reblozyl
January 2024
Japan's Ministry of Health, Labour and Welfare approval of Reblozyl for the treatment of anemia associated with myelodysplastic syndrome.

Refer to "—Product and Pipeline Developments" for a listing of other developments in our marketed products and late-stage pipeline since the start of the third quarter of 2024.

Acquisitions, Divestitures, Licensing and Other Arrangements

Refer to "Item 1. Financial Statements—Note 3. Alliances" and "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for information on significant acquisitions, divestitures, licensing and other arrangements.

39

RESULTS OF OPERATIONS

Regional Revenues

The composition of the changes in revenues was as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions20242023% Change
Foreign Exchange(b)
20242023% Change
Foreign Exchange(b)
United States$8,232 $7,542 9 %— %$25,509 $23,298 9 %— %
International
3,389 3,239 5 %(4)%9,803 9,716 1 %(5)%
Other(a)
271 185 46 %N/A646 515 25 %N/A
Total$11,892 $10,966 8 %(2)%$35,958 $33,529 7 %(2)%
(a)    Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
(b)    Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales.

United States

•U.S. revenues increased 9% during the third quarter of 2024 and year-to-date primarily due to higher demand for the Growth Portfolio and higher demand for Eliquis, partially offset by Sprycel due to generic erosion. Average U.S. net selling prices decreased 1% year-to-date compared to the same period a year ago.

International

•International revenues increased 5% and 1% during the third quarter of 2024 and year-to-date, respectively, driven by higher demand for the Growth Portfolio, partially offset by lower demand for the Legacy Portfolio and foreign exchange impacts. The negative foreign exchange impacts of 4% and 5% during the third quarter and year-to-date, respectively, were primarily attributed to devaluation of the Argentine peso, which was mostly offset by inflation-related local currency price increases.

Beginning in 2024, Puerto Rico revenues are presented as part of International revenues to align with management's review of the Company's financial results. Prior period amounts have been recast to conform to the current presentation. No single country outside the U.S. contributed more than 10% of total revenues during the nine months ended September 30, 2024 and 2023. Our business is typically not seasonal.

GTN Adjustments

The reconciliation of gross product sales to net product sales by each significant category of GTN adjustments was as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions20242023% Change20242023% Change
Gross product sales$21,223 $18,648 14 %$61,298 $54,047 13 %
GTN adjustments
Charge-backs and cash discounts(2,967)(2,373)25 %(8,366)(6,743)24 %
Medicaid and Medicare rebates(4,577)(3,730)23 %(11,525)(9,355)23 %
Other rebates, returns, discounts and adjustments(2,196)(1,900)16 %(6,440)(5,339)21 %
Total GTN adjustments(9,740)(8,003)22 %(26,331)(21,437)23 %
Net product sales$11,483 $10,645 8 %$34,967 $32,610 7 %
GTN adjustments percentage46 %43 %3 %43 %40 %3 %
U.S. 52 %49 %3 %48 %45 %3 %
Non-U.S.20 %20 %— %20 %20 %— %

Reductions to provisions for product sales made in prior periods resulting from changes in estimates were $42 million and $103 million for the three and nine months ended September 30, 2024 and $18 million and $116 million for the three and nine months ended September 30, 2023, respectively. GTN adjustments are primarily a function of product sales volume, regional and payer channel mix, contractual or legislative discounts and rebates. U.S. GTN adjustments percentage increased primarily due to product mix and higher government channel rebates.

40

Product Revenues
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions20242023% Change20242023% Change
Growth Portfolio
Opdivo $2,360 $2,275 4 %$6,825 $6,622 3 %
U.S.1,366 1,343 2 %3,927 3,845 2 %
Non-U.S.994 932 7 %2,898 2,777 4 %
Orencia936 925 1 %2,682 2,616 3 %
U.S.706 708 — %2,020 1,954 3 %
Non-U.S.230 217 6 %662 662 — %
Yervoy642 579 11 %1,855 1,672 11 %
U.S.399 359 11 %1,171 1,039 13 %
Non-U.S.243 220 10 %684 633 8 %
Reblozyl447 248 80 %1,226 688 78 %
U.S.358 200 79 %999 534 87 %
Non-U.S.89 48 85 %227 154 47 %
Opdualag233 166 40 %674 437 54 %
U.S.216 162 33 %637 429 48 %
Non-U.S.17 4 >200%37 8 >200%
Abecma124 93 33 %301 372 (19)%
U.S.77 69 12 %183 302 (39)%
Non-U.S.47 24 96 %118 70 69 %
Zeposia147 123 20 %408 301 36 %
U.S.105 95 11 %288 219 32 %
Non-U.S.42 28 50 %120 82 46 %
Breyanzi224 92 143 %484 263 84 %
U.S.173 77 125 %382 218 75 %
Non-U.S.51 15 >200%102 45 127 %
Camzyos156 68 129 %379 143 165 %
U.S.135 67 101 %342 142 141 %
Non-U.S.21 1 >200%37 1 >200%
Sotyktu66 66 — %163 107 52 %
U.S.51 62 (18)%126 101 25 %
Non-U.S.15 4 >200%37 6 >200%
Augtyro10 — N/A23 — N/A
U.S.10 — N/A23 — N/A
Non-U.S.— — N/A— — N/A
Krazati34 — N/A87 — N/A
U.S.32 — N/A82 — N/A
Non-U.S.2 — N/A5 — N/A
Other Growth Products(a)
433 311 39 %1,093 886 23 %
U.S.172 149 15 %488 455 7 %
Non-U.S.261 162 61 %605 431 40 %
Total Growth Portfolio
$5,812 $4,946 18 %$16,200 $14,107 15 %
U.S.3,800 3,291 15 %10,668 9,238 15 %
Non-U.S.2,012 1,655 22 %5,532 4,869 14 %
41

 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions20242023% Change20242023% Change
Legacy Portfolio
Eliquis$3,002 $2,705 11 %$10,138 $9,332 9 %
U.S.2,045 1,772 15 %7,410 6,610 12 %
Non-U.S.957 933 3 %2,728 2,722 — %
Revlimid1,412 1,429 (1)%4,434 4,647 (5)%
U.S.1,212 1,209 — %3,830 3,951 (3)%
Non-U.S.200 220 (9)%604 696 (13)%
Pomalyst/Imnovid898 872 3 %2,722 2,551 7 %
U.S.697 606 15 %2,010 1,712 17 %
Non-U.S.201 266 (24)%712 839 (15)%
Sprycel 290 517 (44)%1,088 1,404 (23)%
U.S.225 399 (44)%848 1,011 (16)%
Non-U.S.65 118 (45)%240 393 (39)%
Abraxane253 260 (3)%701 757 (7)%
U.S.151 178 (15)%450 526 (14)%
Non-U.S.102 82 24 %251 231 9 %
Other Legacy Products(b)
225 237 (5)%675 731 (8)%
U.S.102 87 17 %293 250 17 %
Non-U.S.123 150 (18)%382 481 (21)%
Total Legacy Portfolio
$6,080 $6,020 1 %$19,758 $19,422 2 %
U.S.4,432 4,251 4 %14,841 14,060 6 %
Non-U.S.1,648 1,769 (7)%4,917 5,362 (8)%
Total Revenues
$11,892 $10,966 8 %$35,958 $33,529 7 %
U.S.8,232 7,542 9 %25,509 23,298 9 %
Non-U.S.(c)
3,660 3,424 7 %10,449 10,231 2 %
    
(a)    Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.
(b)    Includes other mature brands.
(c)    Includes International and Other.

Growth Portfolio

Opdivo (nivolumab) — a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells. It has been approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer. The Opdivo+Yervoy regimen also is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and various gastric and esophageal cancers. There are several ongoing registrational studies for Opdivo across other tumor types and disease areas.

•U.S. revenues increased 2% during the third quarter of 2024 and year-to-date primarily due to higher average net selling prices, partially offset by lower demand.

•International revenues increased 7% during the third quarter of 2024 and 4% year-to-date primarily due to higher demand as a result of additional indication launches and core indications, partially offset by foreign exchange impacts of 9% and 10%, respectively. Excluding foreign exchange impacts, revenues increased 16% and 14%, respectively.

42

Orencia (abatacept) — a fusion protein indicated for adult patients with moderate to severe active RA and PsA and is also indicated for reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular JIA and for the treatment of aGVHD, in combination with a calcineurin inhibitor and methotrexate.

•U.S. revenues were relatively flat during the third quarter of 2024 due to higher demand offset by lower average net selling prices.

•U.S. revenues increased 3% year-to-date primarily due to higher demand, partially offset by lower average net selling prices.

•International revenues increased 6% during the third quarter of 2024 due to higher demand and average net selling price, partially offset by foreign exchange impacts of 7%. Excluding foreign exchange impacts, revenues increased by 13%.

•International revenues were flat year-to-date due to higher demand offset by foreign exchange impacts of 8%. Excluding foreign exchange impacts, revenues increased 8%.

•BMS is not aware of any Orencia biosimilars on the market in the U.S., EU and Japan. Formulation and additional patents expire in 2026 and beyond.

Yervoy (ipilimumab) — a CTLA4 immune checkpoint inhibitor. Yervoy is a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma. The Opdivo+Yervoy regimen is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and esophageal cancer.

•U.S. revenues increased 11% during the third quarter of 2024 and 13% year-to-date due to higher demand and higher average net selling prices.

•International revenues increased 10% during the third quarter of 2024 and 8% year-to-date due to higher demand, partially offset by foreign exchange impacts of 7% in both periods. Excluding foreign exchange impacts, revenues increased by 17% and 15%, respectively.

Reblozyl (luspatercept-aamt) — an erythroid maturation agent indicated for the treatment of anemia in adult patients with lower risk myelodysplastic syndrome and beta thalassemia.

•U.S. revenues increased 79% during the third quarter of 2024 and 87% year-to-date driven by higher demand due to a first line label extension in August 2023.

•International revenues increased 85% during the third quarter of 2024 and 47% year-to-date due to higher demand, partially offset by foreign exchange impacts of 5% and 3%, respectively. Excluding foreign exchange impacts, revenues increased by 90% and 50%, respectively.

Opdualag (nivolumab and relatlimab-rmbw) — a combination of nivolumab, a PD-1 blocking antibody, and relatlimab, a LAG-3 blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

•U.S. revenues increased 33% during third quarter of 2024 and 48% year-to-date primarily due to higher demand.

Abecma (idecabtagene vicleucel) — a BCMA genetically modified autologous CAR–T cell therapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cyclic ADP ribose hydrolase monoclonal antibody.

•U.S. revenues increased 12% during the third quarter of 2024 due to higher demand related to third line label extension in April 2024 and decreased 39% year-to-date due to increased competition in BCMA targeted therapies, partially offset by higher demand related to third line label extension.

Zeposia (ozanimod) — an oral immunomodulatory drug used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and to treat moderately to severely active UC in adults.

•U.S. revenues increased 11% during the third quarter of 2024 and 32% year-to-date primarily due to higher demand.

43

Breyanzi (lisocabtagene maraleucel) — a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL , and relapsed or refractory MCL in patients who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor.

•U.S. revenues increased 125% during the third quarter of 2024 and 75% year-to-date primarily due to higher demand enabled by expanded manufacturing capacity and new indication launches.

Camzyos (mavacamten) — a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive HCM to improve functional capacity and symptoms. Camzyos was launched in April 2022.

•U.S. revenues increased 101% during the third quarter of 2024 and 141% year-to-date, primarily due to higher demand.

Sotyktu (deucravacitinib) — an oral, selective, allosteric tyrosine kinase 2 inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu was launched in September 2022.

•U.S. revenues decreased 18% during the third quarter of 2024 primarily due to comparator sales for use in clinical trials during the third quarter of 2023 and lower average net selling prices, partially offset by higher demand.

•U.S. revenues increased 25% year-to-date, primarily due to higher demand, partially offset by comparator sales for use in clinical trials during the third quarter of 2023 and lower average net selling prices.

Augtyro (repotrectinib) — a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC and for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. Augtyro was launched in November 2023.

Krazati (adagrasib) — a highly selective and potent oral small-molecule inhibitor of the KRASG12C mutation, indicated for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy and, in combination with cetuximab, for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Krazati was brought into the BMS portfolio as part of the Mirati acquisition completed in 2024.

Cobenfy (xanomeline and trospium chloride) – a combination M1 / M4 muscarinic receptor agonist and muscarinic antagonist indicated for the treatment of schizophrenia in adults. Cobenfy was approved by the FDA in September 2024.

Other Growth Brands — includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.

Legacy Portfolio

Eliquis (apixaban) — an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

•U.S. revenues increased 15% during third quarter of 2024 and 12% year-to-date primarily due to higher demand and higher average net selling prices.

•International revenues increased 3% during the third quarter of 2024 and were flat year-to-date primarily due to foreign exchange impacts of 1% and (1)%, respectively. Excluding foreign exchange impacts, revenues increased 2% and 1%, respectively.

•Following the May 2021 expiration of regulatory exclusivity for Eliquis in Europe, generic manufacturers have sought to challenge our Eliquis patents and related SPCs and have begun marketing generic versions of Eliquis in certain countries prior to the expiry of our patents and related SPCs, which has led to the filing of infringement and invalidity actions involving our Eliquis patents and related SPCs being filed in various countries in Europe. We believe in the innovative science behind Eliquis and the strength of our intellectual property, which we will defend against infringement. Refer to "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies—Intellectual Property" for further information.
44


Revlimid (lenalidomide) — an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma. Revlimid as a single agent is also indicated as a maintenance therapy in patients with multiple myeloma following autologous hematopoietic stem cell transplant. Revlimid has received approvals for several indications in the hematological malignancies including lymphoma and MDS.

•U.S. revenues were flat during the third quarter of 2024 and decreased 3% year-to-date primarily due to generic erosion and lower average net selling prices, partially offset by the prior year impact of patients receiving free drug product from the Bristol Myers Squibb Patient Assistance Foundation, a separate and independent 501(c)(3) entity to which BMS donates products.

•International revenues decreased 9% during third quarter of 2024 and 13% year-to-date primarily due to generic erosion across several European countries and foreign exchange impacts of 3% and 4%, respectively. Excluding foreign exchange impacts, revenues decreased by 6% and 9%, respectively.

•In the U.S., certain third parties were granted volume-limited licenses to sell generic lenalidomide beginning in March 2022 or thereafter. Pursuant to these licenses, several generics have entered or are expected to enter the U.S. market with volume-limited quantities of generic lenalidomide. In the EU and Japan, generic lenalidomide products have entered the market.

Pomalyst/Imnovid (pomalidomide) — a proprietary, distinct, small molecule that is administered orally and modulates the immune system and other biologically important targets. Pomalyst/Imnovid is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

•U.S. revenues increased 15% during the third quarter of 2024 and 17% year-to-date due to higher demand and the prior year impact of patients receiving free drug product from the Bristol Myers Squibb Patient Assistance Foundation, a separate and independent 501(c)(3) entity to which BMS donates products.

•International revenues decreased 24% during the third quarter of 2024 and 15% year-to-date primarily due to generic erosion and year-to-date foreign exchange impact of 1%. Excluding foreign exchange impacts, revenues decreased by 24% and 14%, respectively.

•In the EU, generic pomalidomide products entered the market in August 2024.

Sprycel (dasatinib) — an oral inhibitor of multiple tyrosine kinase indicated for the first-line treatment of patients with Philadelphia chromosome-positive CML in chronic phase and the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy, including Gleevec* (imatinib mesylate) and the treatment of children and adolescents aged 1 year to 18 years with chronic phase Philadelphia chromosome-positive CML.

•U.S. revenues decreased 44% during the third quarter of 2024 primarily due to lower average net selling price and generic erosion.

•U.S. revenues decreased 16% year-to-date primarily due to lower average net selling price and generic erosion, partially offset by higher demand during the first half of the year.
•International revenues decreased 45% during the third quarter of 2024 and 39% year-to-date primarily due to generic erosion, lower average net selling prices and foreign exchange impacts of 3% and 4%, respectively. Excluding foreign exchange impacts, revenues decreased by 42% and 35%, respectively.

•In the U.S. (September 2024) and EU, generic dasatinib products have entered the market. In Japan, the composition of matter patent for the treatment of non-imatinib-resistant CML has expired.
45

Abraxane (paclitaxel albumin-bound particles for injectable suspension) — a solvent-free protein-bound chemotherapy product that combines paclitaxel with albumin using our proprietary Nab® technology platform, and is used to treat breast cancer, NSCLC and pancreatic cancer, among others.

•U.S. revenues decreased 15% during the third quarter of 2024 and 14% year-to-date due to lower demand driven by generic erosion.

Other Legacy Portfolio Products — includes other mature brands.

Estimated End-User Demand

Pursuant to the SEC Consent Order described under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation— SEC Consent Order" in our 2023 Form 10-K, we monitor inventory levels on hand in the U.S. wholesaler distribution channel and outside of the U.S. in the direct customer distribution channel. We disclose products with levels of inventory in excess of one month on hand or expected demand, subject to certain limited exceptions. There were none as of September 30, 2024, for our U.S. distribution channels, and as of June 30, 2024, for our non-U.S. distribution channels.

In the U.S., we generally determine our months on hand estimates using inventory levels of product on hand and the amount of out-movement provided by our three largest wholesalers, which accounted for approximately 85% of total gross sales of U.S. products during the nine months ended September 30, 2024. Factors that may influence our estimates include generic erosion, seasonality of products, wholesaler purchases in light of increases in wholesaler list prices, new product launches, new warehouse openings by wholesalers and new customer stockings by wholesalers. In addition, these estimates are calculated using third-party data, which may be impacted by their recordkeeping processes.

Camzyos is only available through a restricted program called the Camzyos REMS Program. Product distribution is limited to REMS certified pharmacies, and enrolled pharmacies must only dispense to patients who are authorized to receive Camzyos. Revlimid and Pomalyst are distributed in the U.S. primarily through contracted pharmacies under the Lenalidomide REMS (Revlimid) and Pomalyst REMS programs, respectively. These are proprietary risk-management distribution programs tailored specifically to provide for the safe and appropriate distribution and use of Revlimid and Pomalyst. Internationally, Revlimid and Imnovid are distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for the products' safe and appropriate distribution and use. These programs may vary by country and, depending upon the country and the design of the risk-management program, the product may be sold through hospitals or retail pharmacies.

Our non-U.S. businesses have significantly more direct customers. Information on available direct customer product level inventory and corresponding out-movement information and the reliability of third-party demand information varies widely. We limit our direct customer sales channel inventory reporting to where we can influence demand. When this information does not exist or is otherwise not available, we have developed a variety of methodologies to estimate such data, including using historical sales made to direct customers and third-party market research data related to prescription trends and end-user demand. Given the difficulties inherent in estimating third-party demand information, we evaluate our methodologies to estimate direct customer product level inventory and to calculate months on hand on an ongoing basis and make changes as necessary. Factors that may affect our estimates include generic competition, seasonality of products, price increases, new product launches, new warehouse openings by direct customers, new customer stockings by direct customers and expected direct customer purchases for governmental bidding situations. As such, all of the information required to estimate months on hand in the direct customer distribution channel for non-U.S. business during the nine months ended September 30, 2024 is not available prior to the filing of this Quarterly Report on Form 10-Q. We will disclose any product with levels of inventory in excess of one month on hand or expected demand for the current quarter, subject to certain limited exceptions, in our Annual report on Form 10-K.

46

Expenses
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions20242023% Change20242023% Change
Cost of products sold(a)
$2,957 $2,506 18 %$9,156 $7,948 15 %
Marketing, selling and administrative1,983 2,003 (1)%6,278 5,699 10 %
Research and development2,374 2,242 6 %7,968 6,821 17 %
Acquired IPRD262 80 *13,343 313 *
Amortization of acquired intangible assets2,406 2,256 7 %7,179 6,769 6 %
Other (income)/expense, net234 (258)*588 (787)*
Total Expenses$10,216 $8,829 16 %$44,512 $26,763 66 %
*    In excess of +/- 100%.
(a)    Excludes amortization of acquired intangible assets.

Cost of Products Sold

Cost of products sold increased by $451 million in the third quarter of 2024 and $1.2 billion year-to-date primarily due to higher profit sharing and royalty expense ($246 million and $565 million) and higher sales volume. Year-to-date 2024 also includes a $280 million impairment charge related to Inrebic.

Marketing, Selling and Administrative

Marketing, selling and administrative expense decreased by $20 million in the third quarter of 2024.

Marketing, selling and administrative expense increased by $579 million year-to-date primarily due to the impact of recent acquisitions in 2024, including the cash settlement of unvested stock awards and other related expenses of $372 million.

Research and Development

Research and development expense increased by $132 million in the third quarter of 2024 primarily due to the impact of recent acquisitions.

Research and development expense increased by $1.1 billion year-to-date primarily due to an IPRD impairment charge relating to alnuctamab ($590 million) and the impact of recent acquisitions, including cash settlement of unvested stock awards and other related expenses of $348 million.

Acquired IPRD

Acquired IPRD charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Karuna asset acquisition (Note 4)$— $— $12,122 $— 
RayzeBio rights buy-out
92 — 92 — 
SystImmune upfront fee (Note 3)— — 800 — 
Evotec designation and opt-in license fees
125 — 170 90 
Prothena opt-in license fee— — 80 55 
Other 45 80 79 168 
Acquired IPRD $262 $80 $13,343 $313 

Amortization of Acquired Intangible Assets

Amortization of acquired intangible assets increased by $150 million in the third quarter of 2024 and $410 million year-to-date primarily due to the intangible assets acquired through the RayzeBio acquisition in the first quarter of 2024 and FDA approval of Augtyro in the fourth quarter of 2023.

47

Other (Income)/Expense, Net

Other (income)/expense, net changed by $492 million in the third quarter of 2024 and $1.4 billion year-to-date as discussed below.

Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Interest expense$505 $280 $1,451 $850 
Royalty and licensing income (180)(365)(532)(1,068)
Royalty income - divestitures(284)(217)(820)(623)
Investment income(94)(107)(364)(304)
Litigation and other settlements— (61)71 (393)
Provision for restructuring78 141 558 321 
Integration expenses 69 54 214 180 
Equity investment (gain)/losses(12)— (221)213 
Acquisition expenses — — 50 — 
Intangible asset impairments
47 29 47 29 
Other105 (12)134 8 
Other (income)/expense, net
$234 $(258)$588 $(787)

•Interest expense increased in the third quarter of 2024 and year-to-date due to additional borrowings. Refer to "Item 1. Financial Statements—Note 10. Financing Arrangements" for further information.
•Royalty income decreased in the third quarter of 2024 and year-to-date primarily due to lower royalty rates for Keytruda* starting in 2024, partially offset by higher royalties from diabetes business divestitures in 2024. Refer to "Item 1. Financial Statements—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for further information.
•Investment income is primarily driven by changes in average cash and marketable debt securities balances.
•Litigation and other settlements includes amounts related to pricing, sales and promotional practices disputes and securities litigation matters, partially offset by income from the Eisai collaboration termination in 2024. Refer to "Item 1. Financial Statements—Note 3. Alliances" and "Item 1. Financial Statements —Note 18. Legal Proceedings and Contingencies" for further information. Third quarter of 2023 includes income related to the AstraZeneca settlement, partially offset by expense recorded in connection with the BeiGene settlement. Year-to-date 2023 includes income related to the Nimbus' TYK2 program change of control provision and additional settlement costs related to commercial disputes regarding intellectual property matters. Refer to "Item 1. Financial Statements—Note 5. Other (Income)/Expense, Net" for further information.
•Provision for restructuring includes exit and other costs primarily related to certain restructuring activities including the plans discussed further in "Item 1. Financial Statements—Note 6. Restructuring".
•Integration expenses increased in the third quarter of 2024 and year-to-date primarily due to Celgene and other acquisitions.
•Equity investments generated gains year-to-date in 2024 compared to losses in 2023 primarily driven by fair value adjustments for investments that have readily determinable fair value. Refer to "Item 1. Financial Statements—Note 9. Financial Instruments and Fair Value Measurements" for more information.
•Acquisition expenses primarily includes investment banking and professional advisory fees.
•Other includes pension settlement charges of $100 million and $119 million for the third quarter of 2024 and year-to-date, respectively, related to the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan.

48

Income Taxes
 Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Earnings/(Loss) before income taxes
$1,676 $2,137 $(8,554)$6,766 
Income tax provision
461 203 455 488 
Effective tax rate27.5 %9.5 %(5.3)%7.2 %
Impact of specified items9.0 %(2.1)%(193.7)%(7.5)%
Effective tax rate excluding specified items18.5 %11.6 %188.4 %14.7 %

Provision for income taxes in interim periods is determined based on the estimated annual effective tax rates and the tax impact of discrete items that are reflected immediately. The effective tax rate for the third quarter of 2024 was primarily impacted by changes in previously estimated annual effective tax rates resulting from jurisdictional earnings mix. The effective tax rate for the third quarter of 2023 was primarily impacted by revised guidance regarding deductibility of certain research and development expenses which reduced income taxes by approximately $160 million and was the primary reason for a $240 million reduction to previously estimated income taxes for 2022 upon finalization of the U.S. federal income tax return.

Excluding the impact of specified items, the effective tax rate increased from 11.6% to 18.5% in the third quarter of 2024, primarily due to the aforementioned jurisdictional earnings mix and revised guidance regarding deductibility of certain research and development expenses.

The year-to-date 2024 effective tax rate was primarily impacted by a $12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna and releases of income tax reserves of $644 million related to the resolution of Celgene's 2017-2019 IRS audit. The Karuna non-tax deductible charge affected the effective tax rate as well as the effective tax rate excluding specified items. In addition, the effective tax rate was impacted by jurisdictional earnings mix resulting from amortization of acquired intangible assets, foreign currency changes on certain net operating loss and other carryforwards in 2024, and other specified items.

The year-to-date 2023 effective tax rate was primarily impacted by a $656 million deferred income tax benefit following the receipt of a non-U.S. tax ruling regarding the deductibility of a statutory impairment of subsidiary investments, jurisdictional earnings mix resulting from amortization of acquired intangible assets, equity investment losses, litigation and other settlements, as well as releases of income tax reserves of $89 million related to the resolution of Celgene's 2009-2011 IRS audit.

Non-GAAP Financial Measures

Our non-GAAP financial measures, such as non-GAAP earnings and related EPS information, are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because the Company believes they neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including (i) amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, (ii) unwinding of inventory purchase price adjustments, (iii) acquisition and integration expenses, (iv) restructuring costs, (v) accelerated depreciation and impairment of property, plant and equipment and intangible assets, (vi) costs of acquiring a priority review voucher, (vii) divestiture gains or losses, (viii) stock compensation resulting from acquisition-related equity awards, (ix) pension, legal and other contractual settlement charges, (x) equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments), (xi) income resulting from the change in control of the Nimbus TYK2 Program and (xii) amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Certain other significant tax items are also excluded such as the impact resulting from a non-U.S. tax ruling regarding the deductibility of a statutory impairment of subsidiary investments and release of income tax reserves relating to the Celgene acquisition. We also provide international revenues for our priority products excluding the impact of foreign exchange. We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are included in Exhibit 99.1 to our Form 8-K filed on October 31, 2024 and are incorporated herein by reference.

49

Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management's, analysts' and investors’ overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. This information is not intended to be considered in isolation or as a substitute for the related financial measures prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

Specified items were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Inventory purchase price accounting adjustments$13 $— $34 $84 
Intangible asset impairment
— — 280 — 
Site exit and other costs88 16 105 53 
Cost of products sold101 16 419 137 
Acquisition related charges(a)
— — 372 — 
Site exit and other costs7 65 19 85 
Marketing, selling and administrative7 65 391 85 
IPRD impairments— 60 590 80 
Priority review voucher— — — 95 
Acquisition related charges(a)
— — 348 — 
Site exit and other costs21 4 36 10 
Research and development21 64 974 185 
Amortization of acquired intangible assets2,406 2,256 7,179 6,769 
Interest expense(b)
(12)(12)(37)(39)
Litigation and other settlements— (62)61 (397)
Provision for restructuring78 141 558 321 
Integration expenses69 54 214 180 
Equity investment (gain)/losses(13)(2)(222)206 
Acquisition expenses— — 50 — 
Intangible asset impairment 47 29 47 29 
Other 106 (1)116 (6)
Other (income)/expense, net275 147 787 294 
Increase to pretax income2,810 2,548 9,750 7,470 
Income taxes on items above(371)(340)(1,296)(944)
Income tax reserve releases
— — (502)— 
Income taxes attributed to non-U.S. tax ruling — — — (656)
Income taxes(371)(340)(1,798)(1,600)
Increase to net earnings$2,439 $2,208 $7,952 $5,870 
(a) Includes cash settlement of unvested stock awards, and other related costs incurred in connection with the recent acquisitions.
(b) Includes amortization of purchase price adjustments to Celgene debt.

50

The reconciliations from GAAP to Non-GAAP were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions, except per share data2024202320242023
Net earnings/(loss) attributable to BMS
GAAP$1,211 $1,928 $(9,020)$6,263 
Specified items2,439 2,208 7,952 5,870 
Non-GAAP$3,650 $4,136 $(1,068)$12,133 
Weighted-average common shares outstanding – diluted2,031 2,064 2,026 2,093 
Diluted earnings/(loss) per share attributable to BMS
GAAP$0.60 $0.93 $(4.45)$2.99 
Specified items1.20 1.07 3.92 2.81 
Non-GAAP$1.80 $2.00 $(0.53)$5.80 
51

FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES

Our net debt position was as follows:
Dollars in MillionsSeptember 30,
2024		December 31,
2023
Cash and cash equivalents$7,890 $11,464 
Marketable debt securities – current204 816 
Marketable debt securities – non-current324 364 
Total cash, cash equivalents and marketable debt securities8,418 12,644 
Short-term debt obligations(1,078)(3,119)
Long-term debt(48,674)(36,653)
Net debt position$(41,334)$(27,128)

We believe that our existing cash, cash equivalents and marketable debt securities, together with our ability to generate cash from operations and our access to short-term and long-term borrowings, are sufficient to satisfy our existing and anticipated cash needs, including dividends, capital expenditures, milestone payments, working capital, income taxes, restructuring initiatives, business development, business combinations, asset acquisitions, repurchase of common stock, debt maturities, as well as any debt repurchases through redemptions or tender offers. During the nine months ended September 30, 2024, our net debt position increased by $14.2 billion primarily driven by payments for acquisitions, collaborations and milestones of $21.8 billion and $3.6 billion of dividend payments, partially offset by cash provided by operations of $10.8 billion.

During the nine months ended September 30, 2024, we issued the 2024 Senior Unsecured Notes in an aggregate principal amount of $13.0 billion with proceeds, net of discount and loan issuance costs, of $12.9 billion. The proceeds from the 2024 Senior Unsecured Notes were used to partially fund the acquisitions of RayzeBio and Karuna, and the remaining net proceeds were used for general corporate purposes. In connection with the issuance of the 2024 Senior Unsecured Notes, we terminated the $10.0 billion 364-day senior unsecured delayed draw term loan facility entered in February 2024 to provide bridge financing for the RayzeBio and Karuna acquisitions.

During the nine months ended September 30, 2024, $2.5 billion 2.900% Notes and $395 million 3.625% Notes matured and were repaid.

Under our commercial paper program, we may issue a maximum of $7.0 billion of unsecured notes that have maturities of not more than 365 days from the date of issuance. During the first quarter of 2024, we issued $3.0 billion of commercial paper and such amount was fully repaid by the end of the third quarter of 2024.

There were no borrowings outstanding under our $5.0 billion revolving credit facility as of September 30, 2024 and December 31, 2023. This credit facility expires in January 2029 and is extendable annually by one year with the consent of the lenders. Additionally, in February 2024, we entered into a $2.0 billion 364-day revolving credit facility, under which no borrowings were outstanding as of September 30, 2024. The facilities provide for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for our commercial paper borrowings.

Dividend payments were $3.6 billion during the nine months ended September 30, 2024. The decision to authorize dividends is made on a quarterly basis by our Board of Directors.

Annual capital expenditures are expected to be approximately $1.3 billion for the full year 2024. We continue to make capital expenditures in connection with the expansion of our manufacturing capabilities, research and development and other facility-related activities.

During the nine months ended September 30, 2024 and 2023, income tax payments were $3.1 billion and $4.1 billion, including $799 million and $567 million, respectively, for the transition tax following the TCJA enactment.

52

Cash Flows

The following is a discussion of cash flow activities:
Nine Months Ended September 30,
Dollars in millions20242023
Cash flow provided by/(used in):
Operating activities$10,751 $9,608 
Investing activities(21,156)(949)
Financing activities$6,769 $(10,383)

Operating Activities

The $1.1 billion increase in cash provided by operating activities compared to 2023, was primarily due to higher customer collections, net of rebates and discounts and alliance payments ($2.6 billion) and lower income tax payments ($1.0 billion), partially offset by acquisition-related expenses, including cash settlement of unvested stock awards ($1.0 billion), and higher interest payments on debt ($500 million), as well as timing of payments in the ordinary course of business.

Investing Activities

The $20.2 billion increase in cash used in investing activities compared to 2023 was due to higher acquisition-related expenses of $21.2 billion, as well as collaboration and milestone payments, partially offset by changes in the amount of marketable debt securities held of $1.0 billion.

Financing Activities

The $17.2 billion change in cash provided by financing activities compared to 2023 was primarily due to net debt borrowings of $10.5 billion in 2024 primarily to fund our acquisitions compared to $5.2 billion repurchases of common stock and net debt repayments of $1.6 billion in 2023.

53

Product and Pipeline Developments

Our R&D programs are managed on a portfolio basis from early discovery through late-stage development and include a balance of early-stage and late-stage programs to support future growth. Our late-stage R&D programs in Phase III development include both investigational compounds for initial indications and additional indications or formulations for marketed products. The following are the developments in our marketed products and our late-stage pipeline since the start of the third quarter of 2024 as of October 31, 2024:

ProductIndicationDateDevelopments
Abecma
Multiple Myeloma
September 2024
Announced the discontinuation of enrollment in the Phase 3 KarMMa-9 study investigating Abecma with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplant.
Augtyro
NSCLC
September 2024
Announced that Japan’s Ministry of Health, Labour and Welfare granted manufacturing and marketing approval for Augtyro for the treatment of patients with ROS1 fusion-positive, unresectable advanced or recurrent NSCLC. This approval is based on results from the Phase 1/2 TRIDENT-1 trial.
Breyanzi
Follicular Lymphoma (FL)August 2024
Announced that Japan's Ministry of Health, Labour and Welfare approved the supplemental NDA for Breyanzi for the treatment of relapsed or refractory FL after one prior line of systemic therapy in patients with high-risk FL and after two or more lines of systemic therapy based on results of the TRANSCEND FL study.
August 2024
Announced EMA validation of the Type II variation application to expand the indication for Breyanzi to include the treatment of adult patients with relapsed or refractory FL who have received two or more prior lines of systemic therapy. The application is based on results of the Phase II TRANSCEND FL study. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process.
Camzyos
oHCM
September 2024
Announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension study evaluating Camzyos in adult patients with New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy demonstrating that patients experienced consistent and sustained improvements in echocardiographic measures and biomarkers after up to 3.5 years of continuous treatment. Patients experienced an improvement in symptoms and functional capacity as measured by NYHA class and patient-reported outcomes. The safety profile of Camzyos for up to 3.5 years remained consistent with the established safety profile and no new safety signals were identified.
July 2024
Announced that the Japanese New Drug Application for Camzyos was accepted by the Pharmaceuticals and Medical Devices Agency for the treatment of obstructive hypertrophic cardiomyopathy. This filing is based on results from the global Phase 3 EXPLORER-HCM and Phase 3 VALOR-HCM trials, as well as the Japan Phase 3 HORIZON-HCM study.
cendakimab
Eosinophilic Esophagitis
July 2024
Announced that the results from the Phase 3 trial evaluating the efficacy and safety of cendakimab in patients with eosinophilic esophagitis met both co-primary endpoints, demonstrating statistically significant reductions versus placebo in symptoms (dysphagia days) and esophageal eosinophil counts after 24 weeks of treatment. The overall safety profile of cendakimab through 48 weeks of treatment in the Phase 3 trial was consistent with previously reported eosinophilic esophagitis Phase 2 trial results, and no new safety signals were identified.
Cobenfy (KarXT; xanomeline and trospium chloride)
Schizophrenia
September 2024
Announced FDA approval of Cobenfy for the treatment of schizophrenia in adults. The approval is based on data from the EMERGENT clinical program, which includes three placebo-controlled efficacy and safety trials and two open-label trials evaluating the long-term safety and tolerability of Cobenfy for up to one year.
Inrebic
Myelofibrosis
August 2024
Announced that the Japanese New Drug Application for Inrebic has been submitted to the Pharmaceuticals and Medical Devices Agency for the treatment of myelofibrosis (MF). This filing is based on results from the global Phase 3 EFC12153 (Jakarta) study for 1L MF, the global Phase 2 ARD12181 (Jakarta-2) study for 2L MF, and the Japan Phase 1/2 FEDR-MF-003 study.


54

ProductIndicationDateDevelopments
Opdivo
NSCLC
October 2024
Announced FDA approval of Opdivo for the treatment of adult patients with resectable (tumors ≥ 4cm or nod positive) NSCLC and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery. The approval is based on results from the Phase 3CheckMate -77T trial.
Opdivo + Yervoy
Melanoma
September 2024
Announced 10-year follow-up data from the Phase 3 CheckMate -067 trial that showed continued durable improvement in survival with first-line Opdivo plus Yervoy therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untreated advanced or metastatic melanoma. With a minimum follow up of 10 years, median overall survival was 71.9 months with Opdivo plus Yervoy, the longest reported median overall survival in a Phase 3 advanced melanoma trial.
HCC
August 2024
Announced FDA acceptance of the supplemental BLA for Opdivo plus Yervoy as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma. The acceptance is based on results from the Phase 3 CheckMate -9DW trial. The FDA assigned a PDUFA goal date of April 21, 2025.
August 2024
Announced that the supplemental Japanese New Drug Application for Opdivo plus Yervoy was accepted by the Pharmaceuticals and Medical Devices Agency for the treatment of unresectable first line hepatocellular carcinoma. This filing is based on results from the Phase 3 CheckMate -9DW study.
July 2024
Announced EMA validation of the Type II variation application for Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable or advanced HCC who have not received prior systemic therapy. The application is based on results from the Phase 3 CheckMate -9DW trial.
Colorectal Cancer
October 2024
Announced that the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to Opdivo monotherapy across all lines of therapy as a treatment for patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer met the dual primary endpoint of progression-free survival as assessed by Blinded Independent Central Review at a pre-specified interim analysis. Previously, Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy.

Opdivo  plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in PFS compared to Opdivo monotherapy across all lines of therapy. The study is ongoing to assess various secondary endpoints, including overall survival. The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data, with no new safety signals identified.
September 2024
Announced that the supplemental Japanese New Drug Application for Opdivo plus Yervoy was accepted by the Pharmaceuticals and Medical Devices Agency for the treatment of unresectable advanced or recurrent colorectal cancer with frequent microsatellite instability. This filing is based on results from the Phase 3 CheckMate -8HW study.
Urothelial Carcinoma
October 2024
Announced that the Phase 3 CheckMate -901 trial evaluating Opdivo plus Yervoy versus standard-of-care non-cisplatin-based chemotherapy in patients with unresectable or metastatic urothelial carcinoma who are ineligible for cisplatin-based chemotherapy, did not meet its primary endpoint of overall survival. The safety profile for Opdivo and Yervoy was consistent with previously reported data, with no new safety signals identified.
 
Opdivo has previously shown clinical benefit across various stages of urothelial carcinoma. These results do not impact those data or approved indications.
Zeposia
Multiple Sclerosis
September 2024
Announced data from the Phase 3 DAYBREAK trial which demonstrated that decreased rates of brain volume loss were sustained in the open-label extension for patients treated with Zeposia for relapsing forms of multiple sclerosis. A separate DAYBREAK OLE safety analysis demonstrated declining or stable incidence rates of treatment-emergent adverse events, with relatively low rates of infections, serious infections and opportunistic infections over more than eight years of treatment with Zeposia.
55


Critical Accounting Policies

The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Our critical accounting policies are those that significantly impact our financial condition and results of operations and require the most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of this uncertainty, actual results may vary from these estimates. For a discussion of our critical accounting policies, refer to "Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations" in our 2023 Form 10-K. There have been no material changes to our critical accounting policies during the nine months ended September 30, 2024. For information regarding the impact of recently adopted accounting standards, refer to "Item 1. Financial Statements—Note 1. Basis of Presentation and Recently Issued Accounting Standards."

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (including documents incorporated by reference) and other written and oral statements we make from time to time contain certain "forward-looking" statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. You can identify these forward-looking statements by the fact they use words such as "should," "could," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe," "will" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on our current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These statements are likely to relate to, among other things, our goals, plans and objectives regarding our financial position, results of operations, cash flows, market position, product development, product approvals, sales efforts, expenses, performance or results of current and anticipated products, our business development strategy and in relation to our ability to realize the projected benefits of our acquisitions, alliances and other business development activities, the impact of any pandemic or epidemic on our operations and the development and commercialization of our products, potential laws and regulations to lower drug prices, market actions taken by private and government payers to manage drug utilization and contain costs, the expiration of patents or data protection on certain products, including assumptions about our ability to retain marketing exclusivity of certain products and the outcome of contingencies such as legal proceedings and financial results. No forward-looking statement can be guaranteed. This Quarterly Report on Form 10-Q, our 2023 Form 10-K, particularly under the section "Item 1A. Risk Factors," and our other filings with the SEC, include additional information on the factors that we believe could cause actual results to differ materially from any forward-looking statement.

Although we believe that we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved and readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. Additional risks that we may currently deem immaterial or that are not presently known to us could also cause the forward-looking events discussed in this Quarterly Report on Form 10-Q not to occur. Except as otherwise required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise after the date of this Quarterly Report on Form 10-Q.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For a discussion of our market risk, refer to "Item 7A. Quantitative and Qualitative Disclosures about Market Risk" in our 2023 Form 10-K. There have been no material changes to our market risk during the nine months ended September 30, 2024.

Item 4. CONTROLS AND PROCEDURES

Management carried out an evaluation, under the supervision and with the participation of its chief executive officer and chief financial officer, of the effectiveness of the design and operation of its disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of September 30, 2024, such disclosure controls and procedures are effective.

There were no changes in the Company's internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II—OTHER INFORMATION
56


Item 1. LEGAL PROCEEDINGS

Information pertaining to legal proceedings can be found in "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies," to the interim consolidated financial statements, and is incorporated by reference herein.

Item 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in the Company's 2023 Form 10-K.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table summarizes the surrenders of our equity securities during the three months ended September 30, 2024: 
Period
Total Number of Shares Purchased(a)
Average Price Paid per Share(a)
Total Number of Shares Purchased as Part of Publicly Announced Programs(b)
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs(b)
Dollars in millions, except per share data    
July 1 to 31, 202421,409 $41.24 — $5,014 
August 1 to 31, 202440,092 $49.15 — $5,014 
September 1 to 30, 202420,232 $49.81 — $5,014 
Three months ended September 30, 202481,733 — 
(a)Includes shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive program.
(b)In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of our common stock. Following this authorization, the Board subsequently approved additional authorizations in February 2020, January and December 2021 and December 2023, in the amounts of $5.0 billion, $2.0 billion, $15.0 billion and $3.0 billion, respectively, to the share repurchase authorization. The remaining share repurchase capacity under the program was $5.0 billion as of September 30, 2024. Refer to "Item 8. Financial Statements and Supplementary Data—Note 17. Equity" in our 2023 Form 10-K for information on the share repurchase program.

Item 5. OTHER INFORMATION

Rule 10b5-1 Trading Arrangement

During the period covered by this Quarterly Report on Form 10-Q, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

57

Item 6. EXHIBITS

Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).
Exhibit No.Description
31a.
31b.
32a.
32b.
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.
101.LABXBRL Taxonomy Extension Label Linkbase Document.
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*    Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.; Gleevec is a trademark of Novartis AG; Keytruda is a trademark of Merck & Co., Inc., Rahway, NJ, USA; Onglyza is a trademark of AstraZeneca AB; Otezla is a trademark of Amgen Inc.; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.

58

SUMMARY OF ABBREVIATED TERMS

Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
2023 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2023MiratiMirati Therapeutics, Inc.
2024 Senior Unsecured NotesAggregate principal amount of $13.0 billion of unsecured senior notes issued by BMS in February 2024MPMmalignant pleural mesothelioma
aGVHDacute graft-versus-host diseaseMTAMethylthioadenosine
ANDAAbbreviated New Drug ApplicationNDANew Drug Application
AstraZenecaAstraZeneca PLCNimbusNimbus Therapeutics
BCMAB-cell maturation antigen-directedNKTnatural killer T
BLA Biologics License ApplicationNSCLCnon-small cell lung cancer
CAR-Tchimeric antigen receptor T-cellNTRKNeurotrophic Tropomyosin Receptor Kinase
CelgeneCelgene CorporationNVAFnon-valvular atrial fibrillation
CERCLAU.S. Comprehensive Environmental Response, Compensation and Liability ActOECDOrganization for Economic Co-operation and Development
CGDPCoverage Gap Discount ProgramOnoOno Pharmaceutical Co., Ltd
CLLChronic Lymphocytic LeukemiaOtsukaOtsuka Pharmaceutical Co., Ltd.
CMLchronic myeloid leukemiaPD-1programmed cell death protein 1
CRCcolorectal carcinomaPD-LIprogrammed death-ligand 1
CTLA4Cytotoxic T-lymphocyte Antigen-4PsApsoriatic arthritis
DLBCLDiffuse Large B-cell LymphomaPRMT5protein arginine methyltransferase 5
ECEuropean CommissionQuarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarter ended September 30, 2024
EisaiEisai Co., Ltd.R&Dresearch and development
EPSearnings per shareRArheumatoid arthritis
EUEuropean UnionRayzeBioRayzeBio, Inc.
Exchange Act the Securities Exchange Act of 1934RCCrenal cell carcinoma
FASBFinancial Accounting Standards BoardRDFVreadily determinable fair values
FDAU.S. Food and Drug AdministrationREMSrisk evaluation and mitigation strategy
FLfollicular lymphomaSanofiSanofi S.A.
GAAPgenerally accepted accounting principlesSECU.S. Securities and Exchange Commission
GTNgross-to-netSLLSmall Lymphocytic Lymphoma
HCChepatocellular carcinomaSPCSupplementary Protection Certificate
HCMhypertrophic cardiomyopathySystImmuneSystImmune, Inc.
IPRDin-process research and developmentTakedaTakeda Pharmaceutical Company Limited
IRAInflation Reduction Act of 2022TCJATax Cuts and Jobs Act
IRSInternal Revenue ServiceTurning PointTurning Point Therapeutics, Inc.
JIAjuvenile idiopathic arthritisUCulcerative colitis
KarunaKaruna Therapeutics, Inc.UKUnited Kingdom
KRASKirsten rat sarcomaU.S.United States
LBCLLarge B-cell LymphomaUSPTOU.S. Patent and Trademark Office
MDSmyelodysplastic syndromesVATvalue added tax
MerckMerck & Co.
59

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 
BRISTOL-MYERS SQUIBB COMPANY
(REGISTRANT)
Date:October 31, 2024By:/s/ Christopher Boerner, Ph.D.
Christopher Boerner, Ph. D.
Chair of the Board and Chief Executive Officer
Date:October 31, 2024By:/s/ David V. Elkins
David V. Elkins
Chief Financial Officer
60